NATIONAL CANCER REGISTRY

Division of the National Health Laboratory Service

health

Department:
Health
REPUBLIC OF SOUTH AFRICA

EKURHULENI POPULATION-BASED CANCER REGISTRY 2021 REPORT

Johannesburg, South Africa, March 2023

Copyright © 2023

Citation:

National Cancer Registry, South Africa. Ekurhuleni Population-Based Cancer Registry 2021 Report. www.ncr.ac.za.

Compiled by:

Babongile Ndlovu (Epidemiologist)

Natasha Abraham (Epidemiologist)

Sizeka Mashele (Epidemiologist)

Dr Mazvita Muchengeti (Acting Head of the Department, Senior Epidemiologist)

Ekurhuleni Population-Based Cancer Registry Surveillance Officers:

Clarence Sibiya

Horatius Simphiwe Javu

Londiwe Nyembe

Mapule Makama

Nelisiwe Fakude

Nomthandazo Dube

Phelade Kale

Siphiwe Mpangani

Ekurhuleni Population-Based Cancer Registry

National Cancer Registry, National Health Laboratory Service

1 Modderfontein Road, Sandringham

Johannesburg

South Africa

2131

Tel: +27 11 555 0548

Fax to email: +27 11 386 6516

Website: www.ncr.ac.za

DISCLAIMER

This report includes all reported cancer cases for Ekurhuleni residents diagnosed from 1st January 2021 to 31st December 2021 as recorded in the Ekurhuleni population-based cancer registry (EPBCR). The information reflects the data at the time of closing the 2021 database for cleaning and analysis on the 31st of January 2023. The EPBCR continues to receive and collect additional data; therefore, the data may be updated as and when necessary. Special requests for data should be directed to the NCR administrator, Ms Evelyn Nkosi, EvelynN@nicd.ac.za.

TABLE OF CONTENTS

DISCLAIMER iii

TABLE OF CONTENTS iv

LIST OF TABLES v

LIST OF FIGURES v

LIST OF APPENDICES v

ACRONYMS AND ABBREVIATIONS vi

FOREWORD viii

EXECUTIVE SUMMARY ix

INTRODUCTION 1

METHODS 3

Data sources 3

Data collection and processes 6

Confidentiality 8

Statistical analysis 9

RESULTS 10

Overall cancer incidence 10

Comparison with the years 2017, 2018, 2019, 2020 & 2021 16

Childhood cancer incidence 19

Data Quality Indicators 20

DISCUSSION 22

CONCLUSION 23

ACKNOWLEDGEMENTS 24

REFERENCES 26

APPENDICES 28

LIST OF TABLES

Table 1: Summary Statistics For All Cancers In Men, Ekurhuleni, 2021 11
Table 2: Summary Statistics For All Cancers In Women, Ekurhuleni, 2021 12
Table 3: Childhood Cancers 2021 19
Table 4: Percentage Of Cases Morphologically Verified (Mv), Diagnosed Clinically Or Diagnosed By Death Certificate Only (Dco), 2021 20

LIST OF FIGURES

Figure 1: Ekurhuleni Population-Based Cancer Registry Data Sources Map, 31 December 2021 5
Figure 2: Ekurhuleni Population-Based Cancer Registry Data Flow Diagram, 2017-2021 7
Figure 3: Percentage Of Cancer Cases By Gender And Race, 2021. 10
Figure 4: Frequency Of Most Common Cancers In Males, Ekurhuleni, 2021 13
Figure 5: Age Standardised Incidence Rates For Common Cancers In Males, Ekurhuleni, 2021 14
Figure 6: Frequency Of Top 10 Common Cancers In Females, Ekurhuleni, 2021 14
Figure 7: Age-Standardised Incidence Rates For Common Cancers In Females, Ekurhuleni, 2021 15
Figure 8: Asr Of Common Cancers In Men By Population Group, Ekurhuleni, 2021 15
Figure 9: Asr Of Common Cancers In Women By Population Group, Ekurhuleni, 2021 16
Figure 10: Age-Standardised Incidence Rates Of The Most Common Cancers In Men, 2017-2021 17
Figure 11: Age-Standardised Incidence Rates Of The Most Common Cancers In Women, 2017-2021 17
Figure 12: Number Of Cancer Cases Reported By Year And Gender, Ekurhuleni, 2017-2021 18

LIST OF APPENDICES

appendix 1: List Of Data Sources 28
Appendix 2: South African Cancer Notification Form 30
Appendix 3: Tables Of Incidence By Site, Sex, Age Group And Population, 2021 31

ACRONYMS AND ABBREVIATIONS

AFCRN	: African Cancer Registry Network
ASR	: Age-Standardised Incidence Rate
CIDERU	: Cancer & Infectious Diseases Epidemiology Research Unit
DoH	: Department of Health, South Africa
DHA	: Department of Home Affairs, South Africa
EPBCR	: Ekurhuleni Population-Based Cancer Registry
IACR	: International Association of Cancer Registries
IARC	: International Agency for Research on Cancer
ICCC	: International Classification of Childhood Cancer
ICDO-3	: International Classification of Diseases for Oncology Third Edition
INCTR	: International Network for Cancer Treatment and Research
KZN PBCR	: Kwazulu-Natal Population-Based Cancer Registry
KZN	: KwaZulu-Natal
LMIC	: Low- or Middle-Income Country
NCDs	: Non-Communicable Disease
NCR	: National Cancer Registry, South Africa
PBCR	: Population-Based Cancer Registry
POPI Act	: Protection of Personal Information Act, South Africa
SA	: South Africa
SAMRC	: South African Medical Research Council
SAOC	: South African Oncology Consortium
STATSSA	: Statistics, South Africa

UICC	: Union for International Cancer Control
UP	: University of Pretoria
WHO	: World Health Organization
WSP	: World Standard Population
CIDERU	: Cancer and Infectious Disease Epidemiology Research Unit
SACCSG	: South African Children's Study Cancer Group

FOREWORD

It gives me great pleasure to make public the 2021 annual report of the Ekurhuleni Population-Based Cancer Registry (EPBCR).

The current report on the EPBCR culminates from support from the National Department of Health, the National Institute for Communicable Diseases, the National Health Laboratory Service, and the work of the National Cancer Registry (NCR) to establish South Africa's first urban population-based cancer registry. The NCR also received support from Takeda Pharmaceuticals to support population-based cancer registration. This is the fifth report to be produced for the EPBCR; previous reports have covered the years 2017 to 2020. While this report provides essential information for healthcare planning locally, the vision for the EPBCR has always been to reach benchmark international standards to report South Africa's cancer incidence rates to the International Agency for Research on Cancer (IARC). With each successive year of operations, the EPBCR has achieved progressively better data quality.

This is not to say that there have been no hurdles. Since the COVID-19 pandemic began, routine cancer surveillance has been more challenging. With some hospital wards closed, outpatient clinics suspended and restrictions on the movement of surveillance officers, high-quality and complete cancer data collection were hindered. In the 2022/2023 financial year, access to hospitals for surveillance officers has improved significantly. The new challenge of high stages of load shedding has made the cancer surveillance work very difficult, with some hospitals not excluded from power cuts and persistent network connectivity issues in some health facilities. However, it is due to the resilience of the staff of the EPBCR that adequate data were collected for the year 2021 resulting in the publication of this report. I would like to commend the staff and stakeholders of the EPBCR for their ongoing commitment to cancer surveillance during these challenging times.

Date: 31 March 2023

Dr Mazvita Muchengeti

(Acting Head of the Department, National Cancer Registry)

EXECUTIVE SUMMARY

It has been more than a decade since the enactment of Regulation No. 380 of the National Health Act (Act 61 of 2003), which formally established the National Cancer Registry (NCR) as its delegated agency for the collection of cancer surveillance information. This regulation made cancer a reportable disease with every healthcare worker obliged to report confirmed cancers to the NCR. In addition, it mandated the NCR to establish population-based cancer registration for the country which led to the establishment and successful implementation of the EPBCR as a pilot site for population-based cancer surveillance in SA.

Despite the NCR operating pathology-based cancer registration since 1986, population-based cancer registration (PBCR) remains the gold standard for cancer surveillance worldwide. It is through comprehensive and quality cancer data that can only be generated by PBCR that the country can effectively drive cancer policy, decision-making, and intervention programmes aimed at reducing cancer cases and deaths. The EPBCR has yielded five years of data since its implementation in 2017.

This report details the fifth year of population-based cancer registration in Ekurhuleni metropolitan municipality, Gauteng province of SA. This includes cancers that were diagnosed between 1st January and 31st December 2021. Data collection for these cancers was conducted in the years 2022 and 2023. Methods of data collection endorsed by the International Agency for Research on Cancer, the International Association of Cancer Registries and the African Cancer Registry Network were employed.

A total of 4631 new cancer cases were registered for the year 2021. The most common cancers registered were prostate, colorectal and lung cancers among males and breast, cervix and colorectal cancer among females. Among children (0-14 years) there were 31 cases registered for 2021. Brain tumours were the most common cancer in children.

The unprecedented COVID-19 pandemic since 2020, and the persistent higher stages of load shedding in SA since 2022 posed many challenges to public health programmes. EPBCR was no exception. The overall case finding and data collection for the year 2021 increased by 32% compared with 3131 in 2020. Some of the challenges to name a few were i) the misinterpretation of POPIA resulting in facilities being less willing to report cancer data and ii) the disruption of cancer care at Charlotte Maxeke Johannesburg Academic Hospital (a major data source for EPBCR) due to the fire in 2021.

Despite the challenges encountered by the EPBCR surveillance officers in data collection, there has been an improvement in access to data sources since the National State of Disaster has been lifted in April 2022. The EPBCR has managed to achieve the goals as outlined in the 2020 cancer incidence report, i.e. capacity building, the official launch of the KZN PBCR, strengthening stakeholder relationships as well as sending the 2017 to 2020 EPBCR incidence reports for evaluation by the International Agency for Research on Cancer (IARC). This report provides valuable information for key stakeholders to guide decision-making, planning of cancer initiatives and intervention programmes, and important data for the evaluation of health interventions.

In the 2023/24 financial year, the NCR will continue to strengthen all their PBCRs (EPBCR and KZN PBCR). The main priorities will be i) to submit the revised and updated EPBCR (2017-2021) to IARC, ii) to continue to strengthen the relationship with the private sector, iii) to ensure that we get access to mortality data, and iv) to enhance the engagement to implement the PBCR in the Western Cape province.

INTRODUCTION

Cancer remains an important public health challenge and the second leading cause of death globally. In 2020, the World Health Organisation (WHO), International Agency for Research on Cancer (IARC) reported an estimated 19.3 million new cancer cases and about 10 million deaths worldwide (1). The distribution of cancer incidence and mortality vary significantly across different regions of the world. Low and middle-income countries (LMICs) are greatly affected and it is estimated that in 2040 about two-thirds of new cancer cases will originate in LMICs (2). The economic implications of the increasing cancer incidence and deaths are catastrophic to both individuals in the community and the public health system (3). Proper evidence-based planning for the future to effectively inform cancer prevention and control policies, intervention programmes and strategies, depends on robust continuous cancer surveillance with quality data (3). It was recognised by many governments during the 2011 United Nations resolution on Non-Communicable Diseases (NCDs) and WHO Global Action for the prevention and control of NCDs for 2013-2020, that population-based cancer registries (PBCRs) are vital components for cancer prevention and control (4). The PBCR gathers information about all cancer cases and deaths for residents within a well-defined geographical area over some time (5). The PBCR is the only tool that can provide the best estimation of the true burden of cancer, monitor epidemiological trends, as well as predict the future cancer burden of the country (5).

In 2011, IARC in partnership with international communities launched the Global Initiative for Cancer Registry Development (GICR) to accelerate PBCR coverage and quality data improvements across the globe (6).

Despite the efforts made by the IARC, there are an estimated 700 cancer registries across the world which cover only about 21% of the world's population (7). In the African region, the PBCR coverage is estimated at 11%. To improve PBCRs coverage and effectiveness of cancer surveillance in sub-Saharan Africa, the International Network for Cancer Treatment and Research (INCTR) established and launched the African Cancer Registry Network (AFCRN) in 2012 (7).

The South African government has made efforts to support the development of PBCR in the country. In 2011, the South African Department of Health enacted Regulation No. 380 of the National Health Act (Act 61 of 2003), which formally established the National Cancer Registry (NCR) as its delegated agency for the collection of cancer surveillance information (3). This

regulation made cancer a reportable disease with every healthcare worker obliged to report confirmed cancers to the NCR (3,4). In addition, it mandated the NCR to establish PBCR for the country. After consultation with local and international cancer surveillance experts, it was decided that a minimum of four population-based cancer registries will be required to confidently extrapolate national cancer incidence. We established the Ekurhuleni Population-Based Cancer Registry (EPBCR) in Gauteng, as the first urban population-based cancer surveillance site in the country in 2015. As reported in the 2020 EPBCR report published on 31 March 2022, for the 2022/23 financial year, we wanted to continue to strengthen the population-based cancer registration by ensuring that the EPBCR data meets international standards, the establishment of PBCRs in SA, capacity building and strengthening stakeholder relationships.

The EPBCR (2017-2020) data has been evaluated internally using the IARC tools (http://www.iacr.com.fr/files/IARCcrgToolsSetup213.zip) to evaluate data quality. It was also submitted to the African Cancer Registry Network (AFRCN) and positive feedback has been received. On 28 February 2023, the KZN PBCR was officially launched in Durban. The KZN PBCR covers the health districts of eThekwini, Umgungundlovu, Zululand and King Cetshwayo. This was achieved through the relationship established between the NCR and the Cancer and Infectious Disease Epidemiology Research Unit (CIDERU) of the University of Kwazulu-Natal to establish the population-based cancer registry in Kwazulu-Natal (KZN). The KZN PBCR is the second PBCR from the four required registries as per the mandate.

The NCR has partnered with the University of Pretoria (UP), School of Medicine to build capacity and develop an interest in oncology services. The EPBCR hosted the UP third-year Medical students from 10 to 21 October 2022 and rotated them throughout the EPBCR data sources to gain access and experience in cancer surveillance in SA as well as to be involved in paediatric cancer surveillance. This initiative was designed to help students gain an understanding and develop an interest in oncology services.

We had a meeting with the Ekurhuleni Department of Health District team in January 2023 to strengthen our strategic partnership and to ensure all the possible data sources can be found. The NCR has initiated engagement with the private sector including the South African Oncology Consortium (SAOC) to ensure adequate coverage of both private and public sector data sources. This is the fifth cancer incidence report for the EPBCR accounting for all reported cancers diagnosed in 2021.

METHODS

The EPBCR employs cancer registration guidelines and strategies developed by the International Association of Cancer Registries (IACR), the International Agency for Research on Cancer (IARC) and the African Cancer Registry Network (AFCRN). In short, the EPBCR employs both passive and active surveillance, collecting data on all cancer patients residing in Ekurhuleni metropolitan municipality diagnosed by clinical, radiological, pathology or any other means of investigation.

Data sources

i. Government and Private Hospitals/Healthcare Facilities

The EPBCR has multiple data sources. The data sources extend beyond the borders of the Ekurhuleni metropolitan municipality due to the nature of the South African healthcare referral system. The municipalities do not often have all levels of care (level 1: Primary health care clinic, Community health care centre, District hospital, level 2: Regional hospital, level 3: Provincial tertiary hospital, and level 4: Central hospital and Specialised hospital) within its borders (8). Therefore, patients may be referred out of the municipality to access further diagnosis and management. Secondly, South African patients are a highly mobile population and have the freedom to choose the healthcare facility they prefer, which is not necessarily within the borders of the district in which they reside.

In addition to the public healthcare facilities, South Africa also has a large and well-resourced private healthcare industry. Sixteen per cent of the South African population has medical health insurance and is thus able to access healthcare in private healthcare facilities. Therefore, to obtain complete reporting from the Ekurhuleni District's population, the EPBCR also collects data from private hospitals, and clinicians in independent private practice (See Appendix 1 for a comprehensive list of data sources).

ii. Laboratories, Oncology Networks and Associations

SA has an expansive network of both public and private laboratories. An estimated 80% of the SA's population is serviced by NHLS, which has over 268 (as of March 2019) laboratories in nine provinces of SA (9). The other estimated 20% of the population is covered by private laboratories which include but are not limited to

Ampath, Pathcare and Lancet laboratories. Both public and private laboratories send electronic reports of patients diagnosed with cancer to the NCR's national pathology surveillance programme. The surveillance officers use all the pathology reports received from laboratories together with other data tools (medical files, hospital register, pharmacy list etc.) to identify, trace and register patients from Ekurhuleni metropolitan municipality into the EPBCR.

In addition, The South African Children's Study Cancer Group (SACCSG) and the South African Oncology Consortium (SAOC) report their relevant data for residents of Ekurhuleni to the NCR. The surveillance officers (SO) use these data sources to consolidate missing information for patients already registered in the EPBCR database or to trace and notify the patient in conjunction with other data tools from different data sources. Finally, SOs use hospital registers, patient files and mortuary records to identify new patients not already recorded in an existing database available to the NCR.

iii. The Hospice

The SOs visit hospices at regular intervals to consolidate information missing for patients already registered from other data sources such as hospitals, as well as to report any new patients identified.

iv. Vital Statistics (Death Registration)

The Department of Home Affairs (DHA) is the custodian of vital statistics for SA. Statistics South Africa (STATS SA) also has cleaned vital statistics data for South Africans that can be used to consolidate vital status (i.e. dead/alive) in the EPBCR. However, STATS SA is unable to legally share patient-level data with other official organisations. To compensate for the challenge, the SOs visit the mortuaries within health facilities to trace and report cases of cancer for patients who may have been missed while alive.

Figure 1 below illustrates the spatial distribution of the data sources for EPBCR as of 31 December 2021.

Figure 1: Ekurhuleni Population-based cancer registry data sources map, 31 December 2021

Data collection and processes

The EPBCR uses both active and passive methods of case finding.

Active case finding:

- The surveillance officers visit healthcare facilities to review electronic and or physical records of patients such as patient files, admission registers, pathology reports, radiology reports, death registers, outpatient registers, pharmacy registers and clinicians' statistical records to notify confirmed cancer cases on the cancer notification forms.

Passive case finding:

- As mentioned above, both the South African Children's Study Cancer Group (SACCSG) and the South African Oncology Consortium (SAOC) passively provide data to the NCR for the Ekurhuleni district.

Inclusion criteria for both active and passive case-finding methods:

- All confirmed cancer cases, in persons who are residents of the Ekurhuleni metropolitan municipality, diagnosed from 1st January to 31 December of the relevant year must be reported to the registry.
- Cancer cases include:
    - Cases considered malignant in the morphology section of the International Classification of Diseases for Oncology (ICD-O); behaviour code-3 are reported to the registry.
    - Cancers in metastatic sites (for example, lymph nodes) are registered with the primary tumour site topography. If this is not known, it is registered as an unknown primary site.

The surveillance officers extract data/variables required (See Appendix 2: South African Cancer Registration Form) from data sources such as medical records and code the cancer diagnosis according to the International Classification of Diseases for Oncology 3rd edition (ICDO-3) for topography and morphology. A pathology report, where available, is filed with the corresponding notification form. Reports are filed according to the date and facility of diagnosis.

The files are then sent to data capturers for data entry on the RedCap system. The NCR uses REDCap instead of the IARC-recommended CanReg system because CanReg did not meet the current data processing requirements, such as large storage capacity, simultaneous multiple users and virtual network use.

Figure 2: Ekurhuleni Population-Based Cancer Registry data flow diagram, 2017-2021

The captured files are sent to the surveillance manager for quality assurance and quality control. The surveillance manager uses both the physical notification forms and electronic records on Redcap for each cancer case to check for duplicates, completeness, and consistency. The files are stored in a locked cabinet for 20 years as per the South Africa Protection of Personal Information Act (POPI Act) before they are permanently destroyed (10). The complete, quality-assured dataset is extracted per year (1st January to 31st December for each year) for cleaning and analysis using Stata software. The analyzed data is then used for annual incidence reports, teaching/training, and research purposes. Figure 2, below illustrates the data processing and flow for the EPBCR.

Confidentiality

The NCR adheres to the NHLS, the IARC and IACR guidelines and the POPI Act to ensure the preservation of privacy during the EPBCR surveillance process (10). Request to use de-identified individual-level EPBCR data by entities/individuals is sought in writing to the NCR. Ethics approval is required before data is granted. The statistics of cancer data are released in an aggregated format through the annual reports published on the NCR website.

Statistical analysis

The results are presented as:

- the number of new cancer cases,
- the percentage of all new cancer cases,
- Age-standardised incidence rate (ASR) per 100,000 and
- The lifetime risk

The results are further stratified by:

- sex (Male and Female),
- population group (Black, White, Asian and Coloured) and
- age groups (5-year interval, e.g.0-5 years, 5-10, 10-15, etc.).

For age standardization, the Segi World Standard Population (WSP) is used as per international cancer registration norms. STATS SA mid-year population data for Ekurhuleni metropolitan municipality is used as a denominator.

The calculation methods are as follows:

$$\textbf{Crude} = \frac{\textbf{Number of new cases}}{\textbf{Mid-year population}} \times 100{,}000$$

$$\textbf{WSP weighting} = \frac{\textbf{WSP (for each age group)}}{\textbf{Total WSP for all age groups}} \times 100{,}000$$

$$\textbf{ASR} = \textbf{Crude X WSP weighting}$$

RESULTS

Overall cancer incidence

A total of 4631 cancer cases were registered by the EPBCR for the year 2021, with 2105 cases (45.5%) occurring in males and 2526 (54.6%) occurring in females. Benign, in-situ cancers and cancers of unknown behaviour were excluded from the data collection and analysis.

Figure 3 below shows the percentage of cancer cases diagnosed in 2021 by gender and race. Forty-two per cent of cases were diagnosed among the White population, 55% among the Black population, while 1% was diagnosed among the Coloured and Asian population groups, respectively.

Figure 3: Percentage of cancer cases by gender and race, 2021.

Tables 1 and 2 illustrate a detailed tabulation of cases registered in 2021 for males and females. The tables show the total number of cases registered, crude rates per 100 000 population, age-adjusted incidence rates per 100 000 population, and lifetime risk for each cancer. Appendix tables further elaborate on these data by demonstrating frequency, age-standardised and age-specific incidence rates by population group and gender.

Table 1: Summary statistics for all cancers in Men, Ekurhuleni: 2021

SITE	ICD10	N*	CRUDE RATE	ASR	CUM RISK 0-74	LIFETIME RISK 0-74
All sites	All	2105	128.17	130.32	15	7
All sites but C44	All but C44	1573	103.33	104.90	12	8
Prostate	C61	513	31.24	33.18	4	23
BCC	C44	394	23.99	24.52	3	38
Colorectal	C18	148	9.01	8.88	1	91
SCC of skin	C44	138	8.40	8.60	1	96
Primary site unknown	C80	96	5.85	5.99	1	135
Lung	C34	80	4.87	5.09	1	155
Non-Hodgkin lymphoma	C84	72	4.38	4.14	0	217
Oesophagus	C15	64	3.90	3.93	1	191
Bladder	C67	50	3.04	3.10	0	277
Melanoma	C43	47	2.86	2.87	0	267
Stomach	C16	41	2.50	2.29	0	386
Kaposi Sarcoma	C46	37	1.89	2.07	0	370
Larynx	C32	31	1.89	1.96	0	359
Naso-Oropharynx	C11	31	2.25	1.92	0	494
Myeloma	C90	26	1.58	1.60	0	513
Pancreas	C25	25	1.52	1.58	0	480
Mouth	C06	24	1.46	1.50	0	525
Brain, CNS	C71	23	1.40	1.33	0	768
Tongue	C02	21	1.28	1.30	0	675
Breast	C50	21	1.28	1.29	0	689
Liver & Bile duct	C22	21	1.28	1.27	0	641
Other specified	C63	19	1.16	1.17	0	648
Penis	C60	19	1.10	1.12	0	900
Leukaemia	C92	18	1.16	1.11	0	983
Eye	C69	18	1.10	1.05	0	1005
Connective tissue	C49	16	0.97	0.94	0	1217
Anus	C21	16	0.97	0.86	0	1238
Testis	C62	16	0.97	0.84	0	1310
Kidney	C64	13	0.79	0.83	0	1093
Hodgkin lymphoma	C81	13	0.67	0.72	0	1624
Skin other	C44	12	0.79	0.70	0	1384
Salivary gland	C07	11	0.73	0.68	0	1585
Ill-defined	C76	6	0.37	0.37	0	2050
Mesothelioma	C45	5	0.30	0.32	0	1240
Haematology other	C96	4	0.24	0.25	0	6192
Gum	C03	3	0.18	0.23	0	5264
Small intestine	C17	3	0.18	0.19	0	6921
Endocrine	C74	3	0.18	0.18	0	6310
Bone	C41	3	0.18	0.13	0	9010
Thyroid	C73	2	0.12	0.11	0	9709
Burkitt lymphoma	C83	1	0.06	0.06	0	20203
Lip	C00	1	0.06	0.06	0	13606

Table 2: Summary statistics for all cancers in Women, Ekurhuleni: 2021

SITE	ICD10	N*	CRUDE RATE	ASR	CUM RISK 0-74	LIFETIME RISK 0-74
All sites	All	2526	145.44	153.48	15	7
All sites but C44	All but C44	2180	131.16	135.99	14	7
Breast	C50	636	36.62	36.94	4	25
Cervix	C53	553	31.84	29.37	3	33
BCC	C44	235	13.53	16.68	1	68
SCC of skin	C44	111	6.39	8.46	1	143
Colorectal	C18	115	6.62	7.88	1	116
Primary site unknown	C80	119	6.85	7.60	1	121
Uterus	C54	90	5.18	6.56	1	126
Vulva	C51	75	4.32	3.53	0	291
Non Hodgkin lymphoma	C84	58	3.34	3.44	0	325
Melanoma	C43	41	2.36	2.89	0	252
Oesophagus	C15	42	2.42	2.72	0	286
Lung	C34	38	2.19	2.65	0	252
Ovary	C56	40	2.30	2.16	0	394
Other specified	C63	36	2.07	2.08	0	401
Pancreas	C25	26	1.50	1.75	0	481
Liver & Bile duct	C22	27	1.55	1.62	0	460
Brain, CNS	C71	21	1.21	1.42	0	866
Anus	C21	23	1.32	1.34	0	793
Bladder	C67	17	0.98	1.08	0	743
Thyroid	C73	18	1.04	1.01	0	954
Hodgkin lymphoma	C81	19	1.09	0.97	0	1180
Myeloma	C90	14	0.81	0.97	0	994
Stomach	C16	16	0.92	0.90	0	892
Vagina	C92	16	0.92	0.90	0	972
Leukaemia	C46	13	0.75	0.84	0	1098
Kaposi Sarcoma	C46	17	0.98	0.78	0	1335
Skin other	C44	11	0.63	0.76	0	1264
Salivary gland	C07	12	0.69	0.74	0	1255
Naso-Oropharynx	C11	11	0.63	0.68	0	979
Mesothelioma	C45	7	0.40	0.53	0	9804
Connective tissue	C49	10	0.58	0.51	0	2504
Kidney	C64	7	0.40	0.49	0	1424
Mouth	C06	7	0.40	0.48	0	1971
Eye	C69	10	0.58	0.47	0	2516
Tongue	C02	6	0.35	0.43	0	2552
Endocrine	C74	6	0.35	0.38	0	3419
Haematology other	C96	6	0.35	0.34	0	3578
Ill defined	C76	6	0.35	0.34	0	2615
Bone	C41	5	0.29	0.33	0	3914
Larynx	C32	3	0.17	0.29	0	13699
Lip	C00	2	0.12	0.12	0	5541
Small intestine	C17	1	0.06	0.07	0	5587

Figure 4-7 below illustrates the frequency and age-standardised incidence rates of the most common cancers registered in the EPBCR in 2021 for males and females. Prostate cancer was by far the most common cancer amongst men with 513 cases and an ASR of 33.18/100 000 population. Amongst women, breast cancer was leading with 636 new cases reported with an ASR of 36.94/100 000. Figures 8 and 9 illustrate the top 5 cancers ASRs by population group. In males, the White population group had the highest ASR in prostate cancer followed Black, Asian then coloured. In females, the White population group had the highest ASR in breast cancer, followed by Black, Coloured then Asian.

Figure 4: Frequency of most common cancers in males, Ekurhuleni, 2021

Figure 5: Age Standardised Incidence Rates for common cancers in males, Ekurhuleni, 2021

Figure 6: Frequency of top 10 common cancers in females, Ekurhuleni, 2021

Figure 7: Age-standardised incidence rates for common cancers in females, Ekurhuleni, 2021

Figure 8: ASR of common cancers in men by population group, Ekurhuleni, 2021

Figure 9: ASR of common cancers in women by population group, Ekurhuleni, 2021

Comparison with the years 2017, 2018, 2019, 2020 & 2021

Figures 10 and 11 show a comparison of reported cancer cases from 2017 to 2021 by gender. There was a 48% increase in the number of cancer cases reported in 2021 (n=4631) vs the year 2020 (n=3131). Among males, there was a 40% increase from 1508 in 2020 while among females there was a 55% increase from 1623 in 2020. The incidence in both males and females is higher in 2021 compared to 2020 in all cancers. The pattern, however, of the most common top 5 cancers age-standardised incidence rates by sex remained the same between 2017 and 2021 with few exceptions for females where lung cancer is replaced by vulvar cancer in 2021.

Figure 10: Age-standardised incidence rates of the most common cancers in men, 2017-2021

Figure 11: Age-standardised incidence rates of the most common cancers in women, 2017-2021

Figure 12: Number of Cancer cases reported by year and gender, Ekurhuleni, 2017-2021

Childhood cancer incidence

Table 3 below shows the top 10 cancers in children aged 0-14 years in the Ekurhuleni area. Thirty-one cancers were registered in 2021 among children. Paediatric cancers accounted for 0.7% of all cancers registered in 2021. There were more cancers in boys than girls. CNS neoplasms, soft tissue sarcomas, retinoblastoma and nephroblastoma were the most common cancers in children.

Table 3: Childhood cancers, Ekurhuleni, 2021

	Number of cases					**Rates per Million Age-Specific Rates**						
Cancer	**Age 0-4**	**Age 5-9**	**Age 10-14**	**All Ages**	**M/F ratio**	**Age 0-4**	**Age 5-9**	**Age 10-14**	**Crude**	**ASR**	**LCL**	**UCL**
Leukaemia	0	2	0	2	1	0	8	0	2.61	2.55	0.31	9.28
Lymphoma	0	0	1	1		0	0	4	1.30	1.28	0.03	7.18
CNS Neoplasms	1	1	3	5	0	3	4	13	6.52	6.46	2.10	15.09
Neuroblastoma	0	0	2	2		0	0	9	2.61	2.55	0.31	9.29
Retinoblastoma	2	1	0	3	2	7	4	0	3.91	3.98	0.82	11.57
Nephroblastoma - Wilms Tumour	1	1	1	3	1	3	4	4	3.91	3.90	0.80	11.41
Bone Tumours	0	1	0	1		0	4	0	1.30	1.28	0.03	7.18
Soft Tissue Sarcomas	0	2	2	4	3	0	8	9	5.22	5.11	1.39	13.12
Germ Cell Tumours	0	0	1	1		0	0	4	1.30	1.28	0.03	7.18
Primary site unknown				0		0	0	0	0.00	0.00	0.00	4.80
Other, specified	4	3	2	9	2	14	12	9	11.74	11.78	5.39	22.36
Total	**8**	**11**	**12**	**31**	**9**	**28**	**43**	**53**	**40.43**	**40.16**	**11.21**	**118.47**

Data Quality Indicators

a) Basis of Diagnosis

Table 4 demonstrates the proportion of cases that were morphologically verified (MV) using histology, cytology or bone marrow aspirate and trephine, diagnosed by clinical means or registered from death certificate-only information (DCO).

Table 4: Percentage of cases Morphologically Verified (MV), diagnosed clinically or diagnosed by Death Certificate Only (DCO), Ekurhuleni, 2021

	(% Total)		Basis of Diagnosis		
ICD 10 Cancer Site	**No. of Cases**	**No.**	**DCO**	**Clinical**	**MV**
C00 Lip	3	0.1	0	0	100
C02 Tongue	27	0.6	0	3.7	96.3
C03 Gum	3	0.1	0	0	100
C06 Mouth	31	0.7	0	0	100
C07 Salivary gland	23	0.5	0	8.7	91.3
C11 Naso-Oropharynx	42	0.9	0	7.1	92.9
C15 Oesophagus	106	2.3	0.9	10.4	88.7
C16 Stomach	57	1.2	0	10.5	89.5
C17 Small intestine	4	0.1	0	0	100
C18-20 Colorectal	263	5.7	0.8	6.5	92.8
C21 Anus	39	0.8	0	12.8	87.2
C22 Liver & Bile duct	48	1	0	45.8	52.1
C25 Pancreas	51	1.1	0	35.3	62.7
C26,C38,C48,C57,C58,C63,C68 Other specified	55	1.2	0	14.5	85.5
C32 Larynx	34	0.7	0	20.6	79.4
C34 Lung	118	2.5	0	33.9	66.1
C41 Bone	8	0.2	12.5	25	50
C43 Melanoma	88	1.9	0	0	100
C44 BCC	629	13.6	0	0.6	98.9
C44 SCC of skin	249	5.4	0	0.4	99.2
C44 Skin other	23	0.5	0	17.4	82.6
C45 Mesothelioma	12	0.3	0	0	100
C46 Kaposi Sarcoma	54	1.2	0	7.4	92.6
C49 Connective tissue	26	0.6	0	30.8	69.2
C50 Breast	657	14.2	0.2	4.3	95.3
C51 Vulva	75	1.6	0	2.7	97.3
C52 Vagina	16	0.3	0	0	100
C53 Cervix	553	11.9	0.2	7.4	92.2
C54 Uterus	90	1.9	0	2.2	97.8
C56 Ovary	40	0.9	0	32.5	67.5

C60 Penis	19	0.4	0	5.3	94.7
C61 Prostate	513	11.1	1.2	8.2	90.4
C62 Testis	16	0.3	0	12.5	87.5
C64 Kidney	20	0.4	0	15	85
C67 Bladder	67	1.4	0	9	91
C69 Eye	28	0.6	0	28.6	71.4
C71 Brain, CNS	44	1	0	31.8	68.2
C73 Thyroid	20	0.4	0	10	90
C74 Endocrine	9	0.2	0	33.3	66.7
C76 Ill-defined	12	0.3	0	25	75
C80 Primary site unknown	215	4.6	0.5	17.7	81.9
C81 Hodgkin lymphoma	32	0.7	3.1	3.1	90.6
C83 Burkitt lymphoma	1	0	0	100	0
C85 Non-Hodgkin lymphoma	130	2.8	0	13.8	86.2
C90 Myeloma	40	0.9	0	7.5	92.5
C92 Leukaemia	31	0.7	0	25.8	71
C96 Haematology other	10	0.2	0	0	100
Total	4,631.00	100	0.3	8.7	90.7

b) Primary site unknown (PSU)

There were 215 cases of cancer (4.6%) reported where the primary site was unspecified or uncertain from the available documentation. The rates of PSU were 5.99 and 7.60 /100 000 in men and women, respectively.

c) Age unknown

There was no record with unknown age.

DISCUSSION

This report covers the fifth year of EPBCR data reporting since 2017. The data presented, reports cancer cases that were diagnosed among residents of Ekurhuleni metropolitan municipality in Gauteng province of South Africa between 1 January and 31 December 2021. Data collection for 2021 cancer cases was conducted in the year 2022/2023 and the database was closed in January 2023. In cancer surveillance, data are always collected retrospectively due to the long turnaround time for diagnosis with a universal standard of a two-year lag, hence the collection of 2021 EPBCR data in 2022 and 2023.

Overall, there were 4631 cases reported by the EPBCR for the year 2021, which is a 48% increase from the year 2020 (3131). However, this increase is likely a data artefact due to the effects of the COVID-19 pandemic on 2020 data. The years 2020 and 2021 have been challenging years for public health surveillance globally. The frequency and age-standardised incidence rates analysis of 2021 EPBCR show that the most common cancers among males were prostate, colorectal and lung, whereas among women the most common cancers were breast, cervix, and colorectal respectively. The frequency of cancers is useful for determining the burden on the country's health care system for screening, diagnosis, treatment and care of cancer patients. On the other hand, age-standardised incidence rates are used to compare rates of cancer between different geographic regions and populations.

The general pattern of cancer among men and women remains similar to previous years with a few exceptions such as bladder cancer and oesophagus reported in the top five cancers among men and vulvar cancer in women. These patterns are almost similar to those of the 2020 GLOBOCAN estimates where bladder cancer is ranked 5th while oesophagus cancer is ranked 6th among the top ten common cancers in men (11). Among children (0-14 years) there were 31 cases registered for 2021. CNS neoplasms were the most common cancers in children. The percentage of morphologically verified cancer cases ranged from 50% to 100%. In the 2023/24 financial year, the NCR will continue to strengthen the EPBCR system and set a benchmark for the other population-based cancer registries in SA to gather comprehensive, representative and best-quality cancer data to inform cancer prevention and control in the country. The NCR in partnership with UKZN-CIDERU launched a KZN PBCR, and in the near future, the cancer incidence from both registries will be computed together to increase the accuracy of the estimates. EPBCR will focus on real-time 2022 data collection (abstraction of cancer cases data

as they get diagnosed), as well as consolidation of the years 2020 and 2021 to correct for the underreporting due to the challenges encountered during the COVID-19 pandemic.

CONCLUSION

Population-based cancer registration is the key for countries to effectively drive cancer policy, decision-making, and intervention programmes which are aimed at reducing cancer cases and deaths. The Ekurhuleni population-based cancer registry has progressively produced five years of quality cancer data for South Africa. Regardless of the challenges encountered such as the COVID-19 pandemic, misinterpretation of POPIA, the Charlotte Maxeke Johannesburg Academic Hospital fire and power cuts, the results of the 2021 EPBCR reports are significant. The increase in reported cancer cases from 2020 to 2021 reflects some restoration of cancer services and surveillance with the progressive relaxation of COVID-19 restrictions in 2021. Overall, the pattern of cancers reported in the year 2021 is similar to that of other countries in the globe as well as the past years of reporting since 2017. The most common cancers registered were prostate, colorectal and lung cancers among males and breast, cervix, and colorectal cancer among females. Among children (0-14 years) the most common cancers were CNS neoplasms, soft tissue sarcomas, retinoblastoma and nephroblastoma, respectively. The EPBCR has set a benchmark for the implementation of the future PBCR in SA and has successfully implemented a second PBCR in KZN.

ACKNOWLEDGEMENTS

This work has been possible through seed funding provided by the South African Medical Research Council. The NCR would also like to thank the National Institute for Communicable Diseases for the continuous support in indirect costs for EPBCR. We would like to thank the National Department of Health for additional funding that has assisted in the continued operations of the EPBCR. The NCR would like to also acknowledge Takeda Pharmaceutical Company Limited for supporting population-based cancer registration activities in EPBCR and the launch of the KZN population-based cancer registry.

The National Cancer Registry (NCR) would also like to thank all individuals, organisations and relevant stakeholders that played a critical role in the operations of the Ekurhuleni Population-Based Cancer Registry.

African Cancer Registry Network (AFCRN)

Tambo Memorial Regional Hospital

Tembisa Regional Hospital

Steve Biko Academic Hospital

Thelle Mogoerane Regional Hospital

Union for International Cancer Control (UICC)

Vermaak Laboratories

World Health Organization (WHO)

South African Medical Research Council (SAMRC)
Ampath Laboratories

Arebaoke Hospice

Benoni Oncology Centre

Chris Hani Baragwanath Academic Hospital

Charlotte Maxeke Academic Hospital

Drs Gritzman & Thatcher Inc Laboratories

Eastrand Benoni Hospice

Edenvale Regional Hospital

Far East Regional Hospital

Gauteng Oncology Alberton Private Hospital

Gauteng Oncology Prostate-Clinic

Gauteng Oncology Linmed Private Hospital

International Agency for Research on Cancer (IARC)

International Association of Cancer Registries (IACR)

Lancet Laboratories

National Department of Health South Africa

National Health Laboratory Services

National Institute for Communicable Diseases

Pathcare Laboratories

Pholosong Regional Hospital

South African Oncology Consortium (SAOC)

South African Paediatric Oncology Network

St Francis Hospice

Stepping Stone Hospice

REFERENCES

1. C P Wild, E Weiderpass BWS (editors). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. Available [Internet]. Vol. 199, Cancer Control. 2020. 512 p. Available from: http://publications.iarc.fr/586

2. ICCP. Cancer Registries ICCP Portal [Internet]. ICCP. 2019 [cited 2020 Nov 19]. Available from: https://www.iccp-portal.org/cancer-registries

3. WHO. Cancer key facts [Internet]. 2020 [cited 2020 Nov 19]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer

4. Assembly UNG. Resolution A/RES/65/238: Scope, modalities, format and organization of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. 2011;11759(April):1–4.

5. IARC. The role and status of population-based cancer registration. 2007; X.

6. IARC. About the GICR [Internet]. 2011 [cited 2021 Mar 29]. Available from: https://gicr.iarc.fr/about-the-gicr/

7. Omonisi AE, Liu B, Parkin DM. Population-Based Cancer Registration in Sub-Saharan Africa: Its Role in Research and Cancer Control. JCO Glob Oncol [Internet]. 2020 Nov 12 [cited 2021 Mar 29];(6):1721–8. Available from: https://ascopubs.org/doi/10.1200/GO.20.00294

8. KwaZulu-Natal Department of Health. Referral system: levels of care [Internet]. 2014 [cited 2019 Feb 19]. p. 2017. Available from: http://www.kznhealth.gov.za/Referral-system.htm

9. NHLS. 2017/18 NHLS Annual Report [Internet]. Sandringham; 2018. Available from: http://www.nhls.ac.za/assets/files/an_report/NHLS_AR_2018.pdf

10. Parliament of the Republic of South Africa. Protection of Personal Information Act, 2013 Ensuring protection of your personal information and effective access to information. 2013 [cited 2019 Mar 27];(4):154. Available from: http://www.justice.gov.za/inforeg/docs/InfoRegSA-POPIA-act2013-004.pdf

11. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global

Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021 May 1 [cited 2022 Mar 30];71(3):209–49. Available from: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21660

APPENDICES

Appendix 1: List of Data Sources

PUBLIC HOSPITALS

- Charlotte Maxeke Johannesburg Academic Hospital
- Chris Hani Baragwanath Academic Hospital
- Steve Biko Academic Hospital
- Tshwane District Hospital
- Pholosong Regional Hospital
- Far East Rand Regional Hospital
- Thelle Mogoerane Regional Hospital
- Tembisa Regional Hospital
- Tambo Memorial Regional Hospital
- Edenvale Hospital

PRIVATE HEALTH FACILITIES

- Benoni Oncology Centre
- Gauteng Prostate Oncology - Morehill Clinic
- Gauteng Oncology - Benoni Oncology Centre
- Gauteng Oncology - Linmed Hospital
- Netcare Clinton Oncology
- Independent Practitioners

HOSPICES

- East Rand Hospice
- Flora Madiba Hospice
- Stepping Stone Hospice
- St Francis Hospice

SOUTH AFRICAN ONCOLOGY CONSORTIUM

- Private Oncologists

PAEDIATRIC ONCOLOGY

- CHOC Childhood cancer foundation
- Chris Hani Baragwanath Academic Hospital
- Steve Biko Academic Hospital
- Donald Gordon Medical Oncology Unit

NHLS

- CDW pathology-based cancer reports

Appendix 2: South African Cancer Notification Form

health
Department:
Health
REPUBLIC OF SOUTH AFRICA

National Health Act, 2003 (Act No. 61 of 2003)
Regulation Number 380

Republic of South Africa
Department of Health

CANCER REGISTRATION FORM

To be completed in duplicate in **BLOCK LETTERS**.
Please mark with ☑ the CORRECT box, where required.
Original to be submitted to the National Cancer Register and copy to be retained:
To be submitted to the National Cancer Register via:
e-mail: cancer.registry@nhls.ac.za
fax: 011 489 9132 / 011 489 9152
Post: PO Box 1038, Johannesburg, 2000

A. PARTICULARS OF INDIVIDUAL

1. Name of facility

USE PATIENT STICKER *if available*

2. Surname

3. Full names

4. Date of birth

5. Folder number

6. Sex ☐ Male ☐ Female

7. ID number/Passport number

8. Race group ☐ African ☐ Coloured ☐ White ☐ Indian ☐ Other _____

9. Area of residence

9.1 City/town/village

9.2 Postal code **9.3 How long at this address?** years

Please record place of birth if not the same as current address

9.4 City/town/village

9.5 Postal code

B. RISK FACTOR PROFILE

10. Usual occupation of patient
(If retired, give type of work done for most of working life)

11. Type of industry/business
(eg Mining, farming etc)

12. Did the patient ever smoke tobacco? ☐ Yes ☐ No ☐ Unknown

13. Did the patient ever consume alcohol regularly? ☐ Yes ☐ No ☐ Unknown
(that is, more than once a week)

14. HIV status ☐ Negative ☐ Positive ☐ Unknown

C. CLINICAL AND LABORATORY DETAILS

15. Date of diagnosis

16. Cancer diagnosis and Histology **17. ICD-10** •

Please give all information available on the site, laterality, histology and behaviour of the tumour

_____

_____

18. Grade ☐ Well differentiated ☐ Moderately differentiated ☐ Poorly differentiated ☐ Unknown/Not applicable

19. Stage ☐ Primary/localised ☐ Metastatic ☐ Unknown/Not applicable

20. Invasiveness ☐ In-situ ☐ Invasive

21. Basis of diagnosis ☐ Clinical ☐ Clinical with investigation ☐ Cytology/histopathology ☐ Molecular ☐ Death Certificate

22. Prescribed treatment ☐ Surgery ☐ Radiation ☐ Chemotherapy ☐ Other ☐ Palliation ☐ Alternative ☐ None

INFORMANT PARTICULARS

Name (Print) _____

MP/NC Number

Signature _____ Date _____

OFFICE CODING

•

M - / /

Appendix 3: Tables of Incidence by site, sex, age group and population, 2021

Tables of ASR and Crude Incidence by population group

Asian Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	**N (Obs)**	**N (Obs) Percent**	**N(Adj)**	**Crude Incidence**	**ASR**	**ASR 95% LCL**	**ASR 95% UCL**
Breast	8	36.36	8	25	24	10	49
Colorectal	3	13.64	3	9	11	2	31
BCC	1	4.55	1	3	4	0	22
Liver & Bile duct	1	4.55	1	3	4	0	22
Thyroid	2	9.09	2	6	4	0	19
Pancreas	1	4.55	1	3	3	0	20
Non Hodgkin lymphoma	1	4.55	1	3	3	0	20
Ovary	1	4.55	1	3	3	0	19
Other specified	1	4.55	1	3	3	0	19
Tongue	1	4.55	1	3	3	0	19
Primary site unknown	1	4.55	1	3	3	0	19
Uterus	1	4.55	1	3	3	0	18

Black Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	**N (Obs)**	**N (Obs) Percent**	**N(Adj)**	**Crude Incidence**	**ASR**	**ASR 95% LCL**	**ASR 95% UCL**
Cervix	506	31,63	506	38,00	39,01	35,54	42,75
Breast	429	26,81	429	32,21	34,36	31,03	37,95
Uterus	78	4,88	78	5,86	8,37	6,59	10,46
Primary site unknown	78	4,88	78	5,86	6,93	5,42	8,73
Colorectal	54	3,38	54	4,05	5,25	3,90	6,88
Vulva	70	4,38	70	5,26	4,58	3,53	5,87
Oesophagus	33	2,06	33	2,48	3,37	2,30	4,74
Non-Hodgkin lymphoma	35	2,19	35	2,63	2,40	1,63	3,44
Ovary	27	1,69	27	2,03	2,09	1,34	3,11
Other specified	27	1,69	27	2,03	2,07	1,33	3,08
SCC of skin	26	1,63	26	1,95	1,90	1,20	2,87
Liver & Bile duct	18	1,13	18	1,35	1,52	0,88	2,44
Pancreas	14	0,88	14	1,05	1,44	0,78	2,42
BCC	16	1,00	16	1,20	1,32	0,74	2,17
Stomach	14	0,88	14	1,05	1,18	0,63	2,03
Lung	11	0,69	11	0,83	1,16	0,58	2,07
Anus	14	0,88	14	1,05	1,02	0,54	1,79
Vagina	13	0,81	13	0,98	1,00	0,52	1,76
Kaposi Sarcoma	15	0,94	15	1,13	0,95	0,52	1,65
Salivary gland	10	0,63	10	0,75	0,84	0,39	1,59
Hodgkin lymphoma	12	0,75	12	0,90	0,76	0,38	1,41
Naso-Oropharynx	9	0,56	9	0,68	0,75	0,33	1,46
Leukaemia	7	0,44	7	0,53	0,67	0,26	1,39
Eye	10	0,63	10	0,75	0,65	0,30	1,26
Thyroid	8	0,50	8	0,60	0,65	0,27	1,32
Melanoma	5	0,31	5	0,38	0,60	0,19	1,35
Brain, CNS	7	0,44	7	0,53	0,57	0,22	1,22
Skin other	6	0,38	6	0,45	0,57	0,19	1,26
Connective tissue	8	0,50	8	0,60	0,52	0,22	1,08
Ill-defined	6	0,38	6	0,45	0,49	0,17	1,12
Tongue	4	0,25	4	0,30	0,43	0,11	1,10
Kidney	4	0,25	4	0,30	0,41	0,11	1,04
Bladder	5	0,31	5	0,38	0,40	0,12	0,98
Bone	4	0,25	4	0,30	0,37	0,10	0,96
Mouth	4	0,25	4	0,30	0,37	0,09	0,96
Endocrine	4	0,25	4	0,30	0,29	0,07	0,81
Larynx	2	0,13	2	0,15	0,27	0,03	0,90
Myeloma	3	0,19	3	0,23	0,26	0,05	0,78
Small intestine	1	0,06	1	0,08	0,11	0,00	0,58
Mesothelioma	1	0,06	1	0,08	0,11	0,00	0,57
Haematology other	1	0,06	1	0,08	0,08	0,00	0,50
Lip	1	0,06	1	0,08	0,08	0,00	0,50

Coloured Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	**N (Obs)**	**N (Obs) Percent**	**N(Adj)**	**CRUDE**	**ASR**	**ASR 95% LCL**	**ASR 95% UCL**
Breast	13	35,14	13	29,14	26,07	13,58	45,81
Cervix	9	24,32	9	20,18	17,63	7,60	35,20
Colorectal	4	10,81	4	8,97	8,12	1,90	22,54
Liver & Bile duct	1	2,70	1	2,24	3,45	0,09	16,67
Leukaemia	1	2,70	1	2,24	3,45	0,09	16,67
Hodgkin lymphoma	1	2,70	1	2,24	2,95	0,07	15,17
Bladder	1	2,70	1	2,24	2,04	0,05	12,66
Non Hodgkin lymphoma	1	2,70	1	2,24	1,90	0,05	12,31
Uterus	1	2,70	1	2,24	1,90	0,05	12,31
Oesophagus	1	2,70	1	2,24	1,86	0,05	12,20
BCC	1	2,70	1	2,24	1,86	0,05	12,20
Vagina	1	2,70	1	2,24	1,86	0,05	12,20
Lung	1	2,70	1	2,24	1,67	0,04	11,74
Primary site unknown	1	2,70	1	2,24	1,67	0,04	11,74

White Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	**N (Obs)**	**N (Obs) Percent**	**N(Adj)**	**CRUDE**	**ASR**	**ASR 95% LCL**	**ASR 95% UCL**
BCC	209	24,79	209	89,46	46,44	39,79	54,10
Breast	185	21,95	185	79,18	43,82	37,36	51,30
SCC of skin	82	9,73	82	35,10	16,04	12,49	20,59
Colorectal	53	6,29	53	22,69	11,25	8,22	15,34
Cervix	33	3,91	33	14,12	9,78	6,64	14,11
Primary site unknown	39	4,63	39	16,69	8,36	5,71	12,12
Melanoma	36	4,27	36	15,41	8,00	5,47	11,63
Lung	25	2,97	25	10,70	5,30	3,26	8,50
Non Hodgkin lymphoma	21	2,49	21	8,99	5,26	2,89	8,95
Brain, CNS	14	1,66	14	5,99	5,04	2,41	9,23
Ovary	11	1,30	11	4,71	3,20	1,56	6,13
Uterus	10	1,19	10	4,28	2,97	1,37	5,88
Pancreas	11	1,30	11	4,71	2,50	1,20	5,06
Bladder	11	1,30	11	4,71	2,27	1,08	4,71
Oesophagus	8	0,95	8	3,42	2,21	0,86	4,94
Thyroid	8	0,95	8	3,42	2,12	0,87	4,69
Hodgkin lymphoma	6	0,71	6	2,57	2,07	0,65	5,03
Anus	9	1,07	9	3,85	2,07	0,89	4,54
Myeloma	11	1,30	11	4,71	1,86	0,90	4,04
Leukaemia	5	0,59	5	2,14	1,57	0,46	4,13
Liver & Bile duct	7	0,83	7	3,00	1,50	0,55	3,79
Other specified	7	0,83	7	3,00	1,48	0,58	3,70
Kidney	3	0,36	3	1,28	1,26	0,12	4,37
Skin other	5	0,59	5	2,14	1,12	0,34	3,29
Haematology other	4	0,47	4	1,71	1,02	0,24	3,27
Vulva	5	0,59	5	2,14	0,84	0,23	2,86
Mouth	3	0,36	3	1,28	0,74	0,14	2,81
Mesothelioma	6	0,71	6	2,57	0,66	0,24	2,48
Connective tissue	2	0,24	2	0,86	0,60	0,07	2,68
Salivary gland	2	0,24	2	0,86	0,47	0,06	2,44
Stomach	2	0,24	2	0,86	0,45	0,05	2,42
Kaposi Sarcoma	1	0,12	1	0,43	0,43	0,01	2,58
Bone	1	0,12	1	0,43	0,39	0,01	2,49
Naso-Oropharynx	2	0,24	2	0,86	0,34	0,04	2,22
Tongue	1	0,12	1	0,43	0,32	0,01	2,33
Vagina	2	0,24	2	0,86	0,29	0,03	2,14
Larynx	1	0,12	1	0,43	0,24	0,01	2,15
Endocrine	1	0,12	1	0,43	0,17	0,00	2,04
Lip	1	0,12	1	0,43	0,17	0,00	2,04

Asian Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	**N (Obs)**	**N (Obs) Percent**	**N(Adj)**	**Crude Incidence**	**ASR**	**ASR 95% LCL**	**ASR 95% UCL**
Prostate	7	26,92	7	19,99	28,92	11,05	62,10
Colorectal	4	15,38	4	11,42	11,71	2,98	35,42
Non Hodgkin lymphoma	3	11,54	3	8,57	9,81	2,00	33,13
Lung	2	7,69	2	5,71	7,51	0,90	30,62
Testis	2	7,69	2	5,71	4,85	0,43	25,85
BCC	2	7,69	2	5,71	4,62	0,42	25,33
Oesophagus	1	3,85	1	2,86	3,58	0,09	24,72
Primary site unknown	1	3,85	1	2,86	3,53	0,09	24,60
Stomach	1	3,85	1	2,86	2,76	0,07	22,97
Mouth	1	3,85	1	2,86	2,69	0,07	22,82
Kidney	1	3,85	1	2,86	2,27	0,06	22,06
Liver & Bile duct	1	3,85	1	2,86	2,27	0,06	22,06

Black Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	**N (Obs)**	**N (Obs) Percent**	**N(Adj)**	**Crude Incidence**	**ASR**	**ASR 95% LCL**	**ASR 95% UCL**
Prostate	316	33,40	316	22,09	36,10	32,07	40,46
Colorectal	69	7,29	69	4,82	5,45	4,15	7,03
Primary site unknown	61	6,45	61	4,26	5,30	3,99	6,90
Lung	48	5,07	48	3,36	4,65	3,36	6,26
Oesophagus	43	4,55	43	3,01	3,82	2,72	5,21
Non Hodgkin lymphoma	45	4,76	45	3,15	3,00	2,14	4,12
Larynx	26	2,75	26	1,82	2,54	1,63	3,76
Kaposi Sarcoma	33	3,49	33	2,31	2,08	1,38	3,05
Stomach	26	2,75	26	1,82	1,82	1,12	2,81
Bladder	20	2,11	20	1,40	1,77	1,02	2,86
Penis	19	2,01	19	1,33	1,48	0,85	2,41
Naso-Oropharynx	16	1,69	16	1,12	1,41	0,79	2,33
Other specified	14	1,48	14	0,98	1,38	0,72	2,37
Mouth	15	1,59	15	1,05	1,33	0,73	2,25
Myeloma	15	1,59	15	1,05	1,29	0,71	2,17
Tongue	15	1,59	15	1,05	1,27	0,70	2,14
Pancreas	14	1,48	14	0,98	1,16	0,61	2,02
Anus	16	1,69	16	1,12	1,12	0,60	1,95
Liver & Bile duct	14	1,48	14	0,98	1,07	0,57	1,87
Eye	16	1,69	16	1,12	1,06	0,59	1,81
SCC of skin	12	1,27	12	0,84	0,87	0,43	1,61
Leukaemia	9	0,95	9	0,63	0,82	0,31	1,70
Breast	10	1,06	10	0,70	0,78	0,35	1,54
Hodgkin lymphoma	12	1,27	12	0,84	0,78	0,39	1,46
Connective tissue	11	1,16	11	0,77	0,73	0,35	1,41
Brain, CNS	8	0,85	8	0,56	0,63	0,23	1,36
Skin other	6	0,63	6	0,42	0,57	0,19	1,30
BCC	5	0,53	5	0,35	0,54	0,17	1,26
Testis	6	0,63	6	0,42	0,39	0,14	0,94
Kidney	5	0,53	5	0,35	0,37	0,12	0,94
Ill defined	4	0,42	4	0,28	0,34	0,09	0,92
Salivary gland	4	0,42	4	0,28	0,32	0,08	0,88
Endocrine	3	0,32	3	0,21	0,21	0,04	0,70
Haematology other	1	0,11	1	0,07	0,18	0,00	0,81
Melanoma	2	0,21	2	0,14	0,15	0,01	0,65
Bone	3	0,32	3	0,21	0,14	0,03	0,57
Mesothelioma	1	0,11	1	0,07	0,13	0,00	0,66
Small intestine	1	0,11	1	0,07	0,12	0,00	0,63
Lip	1	0,11	1	0,07	0,08	0,00	0,54
Burkitt lymphoma	1	0,11	1	0,07	0,06	0,00	0,50

Coloured Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	**N (Obs)**	**N (Obs) Percent**	**N(Adj)**	**Crude Incidence**	**ASR**	**ASR 95% LCL**	**ASR 95% UCL**
Lung	2	16,67	2	4,85	8,61	1,03	30,96
Prostate	3	25,00	3	7,28	8,08	1,48	27,88
Non Hodgkin lymphoma	2	16,67	2	4,85	4,62	0,56	22,15
Kaposi Sarcoma	2	16,67	2	4,85	3,67	0,44	20,41
Brain, CNS	1	8,33	1	2,43	2,81	0,07	20,20
Naso-Oropharynx	1	8,33	1	2,43	1,92	0,05	18,38
Colorectal	1	8,33	1	2,43	1,22	0,03	17,27

White Males: Crude and Age-Adjusted Incidence Rates/100 000							
Site	**N (Obs)**	**N (Obs) Percent**	**N(Adj)**	**Crude Incidence**	**ASR**	**ASR 95% LCL**	**ASR 95% UCL**
BCC	382	34,66	382	165,94	92,03	82,66	102,39
Prostate	184	16,70	184	79,93	41,54	35,54	48,52
SCC of skin	125	11,34	125	54,30	26,70	22,06	32,32
Colorectal	72	6,53	72	31,28	17,79	13,48	23,24
Melanoma	44	3,99	44	19,11	10,83	7,65	15,13
Primary site unknown	34	3,09	34	14,77	8,39	5,67	12,24
Bladder	29	2,63	29	12,60	7,33	4,50	11,44
Lung	28	2,54	28	12,16	7,10	4,57	10,80
Oesophagus	18	1,63	18	7,82	5,17	2,85	8,81
Non Hodgkin lymphoma	20	1,81	20	8,69	4,73	2,81	7,82
Brain, CNS	14	1,27	14	6,08	4,02	2,07	7,27
Naso-Oropharynx	14	1,27	14	6,08	3,37	1,81	6,15
Testis	8	0,73	8	3,48	2,86	1,20	5,93
Stomach	14	1,27	14	6,08	2,75	1,43	5,28
Breast	11	1,00	11	4,78	2,64	1,29	5,25
Pancreas	11	1,00	11	4,78	2,62	1,28	5,21
Myeloma	10	0,91	10	4,34	2,53	1,19	5,15
Leukaemia	9	0,82	9	3,91	2,05	0,81	4,64
Mouth	8	0,73	8	3,48	2,04	0,87	4,50
Tongue	6	0,54	6	2,61	1,84	0,67	4,37
Kidney	7	0,64	7	3,04	1,65	0,64	3,99
Salivary gland	7	0,64	7	3,04	1,50	0,57	3,77
Connective tissue	5	0,45	5	2,17	1,49	0,48	3,89
Larynx	5	0,45	5	2,17	1,49	0,37	4,14
Skin other	6	0,54	6	2,61	1,44	0,50	3,72
Liver & Bile duct	6	0,54	6	2,61	1,35	0,47	3,57
Other specified	5	0,45	5	2,17	1,32	0,40	3,66
Gum	3	0,27	3	1,30	0,95	0,19	3,20
Kaposi Sarcoma	2	0,18	2	0,87	0,89	0,09	3,40
Mesothelioma	4	0,36	4	1,74	0,71	0,19	2,65
Haematology other	3	0,27	3	1,30	0,67	0,12	2,72
Thyroid	2	0,18	2	0,87	0,63	0,08	2,75
Small intestine	2	0,18	2	0,87	0,52	0,06	2,54
Ill defined	2	0,18	2	0,87	0,42	0,05	2,36
Hodgkin lymphoma	1	0,09	1	0,43	0,30	0,01	2,28
Eye	1	0,09	1	0,43	0,18	0,00	2,04

Age-Specific Incidence Rates /100 000 and Lifetime Risk reported as 1: x

ALL FEMALES																			
Site	**0-4**	**5-9**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**	**LR74**
All sites	3,48	5,46	6,18	8,81	8,52	31,68	82,62	139,79	158,54	248,82	240,40	357,45	641,95	529,12	801,35	897,74	1797,72	1660,83	7
All sites but C44	3,48	5,46	6,18	5,29	7,87	30,01	77,53	136,41	147,79	233,69	230,34	317,90	570,39	451,69	722,64	686,51	1419,25	1245,62	7
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,64	2,82	0,00	5,04	1,12	2,93	4,09	8,60	0,00	0,00	18,92	27,68	793
BCC	0,00	0,00	0,00	0,88	0,00	1,67	3,81	3,38	10,08	15,13	10,06	36,62	69,51	75,28	71,55	211,23	378,47	415,21	68
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,13	1,34	0,00	1,12	1,46	6,13	8,60	7,15	7,54	18,92	0,00	743
Bone	0,00	1,56	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,84	0,00	0,00	2,04	0,00	0,00	0,00	0,00	0,00	3914
Brain, CNS	0,70	0,78	1,77	0,00	0,00	1,11	1,27	0,56	0,00	0,00	3,35	4,39	2,04	0,00	7,15	0,00	37,85	27,68	866
Breast	0,00	0,00	0,00	0,00	1,31	10,00	17,79	38,33	48,37	80,70	69,32	79,11	159,46	111,85	196,76	218,78	264,93	221,44	25
Cervix	1,39	0,00	0,00	0,00	0,00	6,11	26,06	45,66	53,07	73,13	65,97	105,48	120,62	55,92	71,55	67,90	113,54	27,68	33
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	3,81	1,69	0,67	5,88	19,01	14,65	44,98	32,26	50,08	67,90	151,39	83,04	116
Connective tissue	0,00	0,00	0,88	0,00	0,66	1,67	0,00	0,56	1,34	0,84	0,00	0,00	2,04	0,00	0,00	0,00	0,00	0,00	2504
Endocrine	0,70	0,00	1,77	0,00	0,00	0,00	0,00	0,56	0,67	0,00	0,00	0,00	0,00	2,15	0,00	0,00	0,00	0,00	3419
Eye	0,00	0,78	0,00	0,00	0,00	0,00	0,64	1,13	3,36	0,00	0,00	0,00	2,04	0,00	0,00	0,00	0,00	0,00	2516
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,56	0,00	0,00	0,00	4,39	0,00	0,00	0,00	0,00	18,92	0,00	3578
Hodgkin lymphoma	0,00	0,00	0,00	1,76	1,31	0,00	0,64	3,38	1,34	1,68	1,12	0,00	0,00	2,15	3,58	0,00	18,92	0,00	1180
Ill defined	0,00	0,00	0,00	0,00	0,66	0,00	0,00	0,00	1,34	0,00	0,00	1,46	2,04	2,15	0,00	0,00	0,00	0,00	2615
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	1,11	1,27	2,82	1,34	1,68	1,12	1,46	2,04	2,15	0,00	0,00	0,00	0,00	1335
Kidney	0,70	0,78	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,12	0,00	0,00	4,30	7,15	0,00	0,00	0,00	1424
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,46	0,00	0,00	0,00	0,00	18,92	27,68	13699
Leukaemia	0,00	0,78	0,00	0,00	0,00	0,56	0,64	0,56	0,00	0,84	0,00	1,46	4,09	2,15	7,15	7,54	18,92	0,00	1098
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,46	0,00	2,15	0,00	0,00	0,00	0,00	5541
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,13	1,34	5,04	5,59	0,00	6,13	6,45	17,89	0,00	18,92	0,00	460
Lung	0,00	0,00	0,00	0,00	0,00	0,56	0,64	0,00	0,00	0,84	0,00	4,39	12,27	21,51	39,35	22,63	37,85	0,00	252
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,64	1,13	0,00	0,84	3,35	1,46	18,40	10,75	42,93	45,26	0,00	27,68	252

Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,04	0,00	0,00	45,26	0,00	0,00	9804
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,00	0,00	0,00	1,12	0,00	4,09	4,30	0,00	0,00	18,92	0,00	1971
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,00	0,00	5,86	0,00	6,45	7,15	7,54	56,77	0,00	994
Naso-Oropharynx	0,00	0,00	0,00	0,88	0,00	0,00	0,00	1,13	0,67	0,00	0,00	2,93	4,09	0,00	10,73	0,00	0,00	0,00	979
Non Hodgkin lymphoma	0,00	0,78	0,88	0,88	2,62	1,11	4,45	4,51	2,69	4,20	3,35	4,39	8,18	12,91	10,73	7,54	37,85	83,04	325
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,56	0,64	0,56	1,34	1,68	10,06	4,39	2,04	23,66	25,04	7,54	18,92	55,36	286
Other specified	0,00	0,00	0,00	0,00	0,66	1,67	2,54	1,69	0,67	1,68	5,59	4,39	8,18	8,60	14,31	7,54	18,92	0,00	401
Ovary	0,00	0,00	0,88	0,88	0,00	1,11	1,91	3,38	2,69	4,20	4,47	2,93	6,13	15,06	7,15	0,00	0,00	0,00	394
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	1,68	2,24	10,25	8,18	15,06	3,58	0,00	18,92	27,68	481
Primary site unknown	0,00	0,00	0,00	0,88	0,66	2,78	1,91	3,95	3,36	12,61	8,95	17,58	34,76	27,96	50,08	75,44	132,46	27,68	121
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,56	2,54	2,25	6,05	6,72	5,59	10,25	24,53	17,21	64,39	67,90	170,31	470,57	143
Salivary gland	0,00	0,00	0,00	2,64	0,66	0,00	1,27	0,00	0,67	0,00	0,00	2,93	2,04	2,15	3,58	0,00	0,00	0,00	1255
Skin other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,13	0,00	0,00	1,12	4,39	2,04	0,00	7,15	0,00	18,92	27,68	1264
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,58	0,00	0,00	0,00	5587
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	1,27	0,56	0,67	2,52	1,12	1,46	4,09	10,75	0,00	0,00	0,00	0,00	892
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	1,27	1,69	0,67	2,52	0,00	4,39	6,13	4,30	0,00	0,00	18,92	0,00	954
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,68	1,12	1,46	0,00	0,00	3,58	0,00	0,00	27,68	2552
Uterus	0,00	0,00	0,00	0,00	0,00	0,56	0,00	1,69	1,34	2,52	5,59	11,72	61,33	27,96	46,51	22,63	113,54	83,04	126
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	1,91	0,56	0,00	4,20	1,12	1,46	2,04	2,15	7,15	0,00	18,92	0,00	972
Vulva	0,00	0,00	0,00	0,00	0,00	0,56	3,81	11,27	11,42	10,09	6,71	4,39	4,09	2,15	14,31	7,54	37,85	0,00	291

ASIAN FEMALES																			
Site	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**	**LR74**
All sites	0,00	0,00	0,00	0,00	0,00	0,00	27,14	65,80	77,14	198,86	201,51	70,25	508,83	414,21	0,00	0,00	0,00	0,00	13
All sites but C44	0,00	0,00	0,00	0,00	0,00	0,00	27,14	65,80	77,14	198,86	201,51	70,25	407,07	414,21	0,00	0,00	0,00	0,00	14
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	101,77	0,00	0,00	0,00	0,00	0,00	197
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	32,90	77,14	99,43	0,00	0,00	203,53	103,55	0,00	0,00	0,00	0,00	39
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	67,17	0,00	101,77	103,55	0,00	0,00	0,00	0,00	74
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	101,77	0,00	0,00	0,00	0,00	0,00	197
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	67,17	0,00	0,00	0,00	0,00	0,00	0,00	0,00	298
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	103,55	0,00	0,00	0,00	0,00	194

BLACK FEMALES																			
Site	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**	**LR74**
All sites	3,18	4,60	4,07	8,22	8,59	31,96	89,68	165,94	192,31	298,31	244,49	327,57	504,87	490,14	521,08	403,45	637,90	467,83	7
All sites but C44	3,18	4,60	4,07	5,13	7,81	31,27	87,22	165,94	190,31	290,59	244,49	319,23	499,30	486,25	504,27	390,44	637,90	467,83	8
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,82	3,91	0,00	3,86	0,00	4,17	5,58	3,89	0,00	0,00	0,00	0,00	900
BCC	0,00	0,00	0,00	0,00	0,00	0,69	0,82	0,00	1,00	7,71	0,00	8,35	2,79	0,00	5,60	13,01	0,00	0,00	742
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,78	2,00	0,00	0,00	0,00	2,79	3,89	0,00	0,00	0,00	0,00	2115
Bone	0,00	1,84	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,29	0,00	0,00	2,79	0,00	0,00	0,00	0,00	0,00	3379
Brain, CNS	0,79	0,92	0,00	0,00	0,00	0,00	1,65	0,00	0,00	0,00	1,66	2,09	0,00	0,00	0,00	0,00	23,63	0,00	2813
Breast	0,00	0,00	0,00	0,00	1,56	12,51	20,57	43,83	60,10	96,44	73,18	60,51	131,10	124,48	134,47	117,13	118,13	93,57	27
Cervix	0,79	0,00	0,00	0,00	0,00	6,95	31,27	60,27	74,12	99,01	88,15	141,88	147,84	81,69	106,46	104,12	141,76	31,19	24
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	2,47	1,57	1,00	6,43	14,97	8,35	44,63	19,45	16,81	26,03	70,88	31,19	173
Connective tissue	0,00	0,00	1,02	0,00	0,78	2,08	0,00	0,00	2,00	1,29	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2790
Endocrine	0,79	0,00	1,02	0,00	0,00	0,00	0,00	0,78	1,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5572
Eye	0,00	0,92	0,00	0,00	0,00	0,00	0,82	1,57	5,01	0,00	0,00	0,00	2,79	0,00	0,00	0,00	0,00	0,00	1801
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,09	0,00	0,00	0,00	0,00	0,00	0,00	9570
Hodgkin lymphoma	0,00	0,00	0,00	1,03	0,00	0,00	0,82	3,91	2,00	2,57	0,00	0,00	0,00	0,00	5,60	0,00	0,00	0,00	1256
Ill defined	0,00	0,00	0,00	0,00	0,78	0,00	0,00	0,00	2,00	0,00	0,00	2,09	2,79	3,89	0,00	0,00	0,00	0,00	1732
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	1,39	0,82	3,91	2,00	2,57	1,66	2,09	0,00	3,89	0,00	0,00	0,00	0,00	1092
Kidney	0,79	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,66	0,00	0,00	7,78	0,00	0,00	0,00	0,00	1956
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	23,63	31,19	
Leukaemia	0,00	0,92	0,00	0,00	0,00	0,00	0,82	0,00	0,00	1,29	0,00	2,09	0,00	3,89	0,00	13,01	23,63	0,00	2220
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,09	0,00	0,00	0,00	0,00	0,00	0,00	9570
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,57	1,00	7,71	6,65	0,00	5,58	7,78	5,60	0,00	0,00	0,00	558
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,26	2,79	15,56	16,81	0,00	0,00	0,00	483
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	15,56	0,00	13,01	0,00	0,00	1286
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,79	0,00	0,00	0,00	0,00	0,00	7169
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,82	0,00	0,00	0,00	1,66	0,00	0,00	3,89	0,00	0,00	23,63	0,00	3140
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,00	0,00	0,00	2,09	0,00	0,00	5,60	0,00	0,00	0,00	2302

Naso-Oropharynx	0,00	0,00	0,00	1,03	0,00	0,00	0,00	1,57	1,00	0,00	0,00	4,17	5,58	0,00	5,60	0,00	0,00	0,00	1056
Non Hodgkin lymphoma	0,00	0,00	1,02	1,03	3,12	1,39	4,94	6,26	3,00	3,86	1,66	2,09	5,58	3,89	5,60	0,00	0,00	31,19	461
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,82	0,00	1,00	2,57	11,64	4,17	2,79	42,79	33,62	13,01	0,00	31,19	202
Other specified	0,00	0,00	0,00	0,00	0,78	2,08	3,29	2,35	1,00	2,57	8,32	4,17	2,79	7,78	5,60	13,01	23,63	0,00	492
Ovary	0,00	0,00	1,02	1,03	0,00	1,39	2,47	3,91	2,00	3,86	3,33	2,09	2,79	19,45	5,60	0,00	0,00	0,00	409
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,57	0,00	8,35	8,37	11,67	5,60	0,00	0,00	31,19	548
Primary site unknown	0,00	0,00	0,00	1,03	0,78	2,78	1,65	5,48	3,00	15,43	11,64	22,95	27,89	31,12	28,02	52,06	47,25	31,19	132
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	3,29	3,13	6,01	7,71	0,00	2,09	5,58	3,89	5,60	0,00	0,00	31,19	537
Salivary gland	0,00	0,00	0,00	3,08	0,78	0,00	1,65	0,00	1,00	0,00	0,00	0,00	2,79	3,89	5,60	0,00	0,00	0,00	1065
Skin other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,78	0,00	0,00	1,66	4,17	0,00	0,00	5,60	0,00	0,00	31,19	1639
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,60	0,00	0,00	0,00	3572
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	1,65	0,78	1,00	3,86	1,66	2,09	2,79	15,56	0,00	0,00	0,00	0,00	681
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,82	0,78	0,00	2,57	0,00	4,17	2,79	3,89	0,00	0,00	0,00	0,00	1332
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,66	2,09	0,00	0,00	5,60	0,00	0,00	31,19	2140
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,35	2,00	2,57	3,33	12,52	72,52	50,57	72,84	39,04	141,76	62,38	92
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	2,47	0,78	0,00	6,43	0,00	2,09	2,79	0,00	11,21	0,00	0,00	0,00	777

COLOURED FEMALES																			
Site	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**	**LR74**
All sites	31,42	0,00	0,00	32,76	0,00	0,00	61,22	37,95	22,16	190,48	260,57	204,42	66,48	445,06	689,45	0,00	0,00	0,00	10
All sites but C44	31,42	0,00	0,00	32,76	0,00	0,00	61,22	37,95	22,16	190,48	223,34	204,42	66,48	445,06	689,45	0,00	0,00	0,00	10
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	37,22	0,00	0,00	0,00	0,00	0,00	0,00	0,00	538
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	51,11	0,00	0,00	0,00	0,00	0,00	0,00	392
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	63,49	74,45	102,21	66,48	278,16	172,36	0,00	0,00	0,00	27
Cervix	31,42	0,00	0,00	0,00	0,00	0,00	61,22	18,98	22,16	63,49	37,22	51,11	0,00	0,00	0,00	0,00	0,00	0,00	71
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18,98	0,00	0,00	37,22	0,00	0,00	55,63	172,36	0,00	0,00	0,00	71
Hodgkin lymphoma	0,00	0,00	0,00	32,76	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	611
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	172,36	0,00	0,00	0,00	117
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	172,36	0,00	0,00	0,00	117
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	55,63	0,00	0,00	0,00	0,00	360
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	31,75	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	630
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	37,22	0,00	0,00	0,00	0,00	0,00	0,00	0,00	538
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	55,63	0,00	0,00	0,00	0,00	360
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	31,75	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	630
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	37,22	0,00	0,00	0,00	0,00	0,00	0,00	0,00	538

WHITE FEMALES																			
Site	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**	**LR74**
All sites	0,00	18,36	18,88	8,33	14,46	71,93	121,46	163,12	254,28	286,60	347,94	479,93	849,70	619,32	1057,55	941,70	1515,99	1319,49	5
All sites but C44	0,00	18,36	18,88	0,00	14,46	58,85	92,88	131,55	169,52	227,11	298,24	343,65	632,00	422,53	904,03	646,05	1079,57	899,65	7
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,22	6,21	0,00	0,00	17,36	0,00	0,00	22,97	29,99	503
BCC	0,00	0,00	0,00	8,33	0,00	13,08	28,58	31,57	84,76	59,48	49,71	124,43	217,69	196,79	153,51	295,65	436,42	419,84	21
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,26	0,00	0,00	6,21	0,00	14,04	17,36	17,06	10,95	22,97	0,00	334
Bone	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,52	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3068
Brain, CNS	0,00	0,00	18,88	0,00	0,00	13,08	0,00	5,26	0,00	0,00	12,43	11,85	7,02	0,00	17,06	0,00	22,97	29,99	234
Breast	0,00	0,00	0,00	0,00	0,00	0,00	21,43	57,88	65,20	91,93	99,41	136,28	196,62	81,03	247,33	219,00	206,73	149,94	21
Cervix	0,00	0,00	0,00	0,00	0,00	6,54	7,14	15,79	19,56	43,26	24,85	17,78	28,09	28,94	8,53	0,00	0,00	0,00	100
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	21,43	0,00	0,00	10,81	37,28	35,55	35,11	46,30	85,29	76,65	91,88	59,98	74
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,26	0,00	0,00	0,00	0,00	7,02	0,00	0,00	0,00	0,00	0,00	1629
Endocrine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,79	0,00	0,00	0,00	0,00	3455
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	7,14	0,00	0,00	0,00	0,00	11,85	0,00	0,00	0,00	0,00	22,97	0,00	1054
Hodgkin lymphoma	0,00	0,00	0,00	0,00	14,46	0,00	0,00	5,26	0,00	0,00	6,21	0,00	0,00	5,79	0,00	0,00	22,97	0,00	631
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,00	7,14	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2802
Kidney	0,00	9,18	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	17,06	0,00	0,00	0,00	763
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,93	0,00	0,00	0,00	0,00	0,00	0,00	3373
Leukaemia	0,00	0,00	0,00	0,00	0,00	6,54	0,00	5,26	0,00	0,00	0,00	0,00	14,04	0,00	8,53	0,00	0,00	0,00	582
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,79	0,00	0,00	0,00	0,00	3455
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,52	0,00	6,21	0,00	0,00	5,79	25,59	0,00	22,97	0,00	454
Lung	0,00	0,00	0,00	0,00	0,00	6,54	7,14	0,00	0,00	5,41	0,00	0,00	35,11	28,94	59,70	32,85	45,94	0,00	141
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	7,14	10,52	0,00	5,41	18,64	5,93	63,20	5,79	102,34	54,75	0,00	29,99	92
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	65,70	0,00	0,00	
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	14,04	5,79	0,00	0,00	0,00	0,00	1009
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	17,78	0,00	17,36	8,53	10,95	68,91	0,00	458

Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	17,06	0,00	0,00	0,00	1173
Non Hodgkin lymphoma	0,00	9,18	0,00	0,00	0,00	0,00	7,14	0,00	6,52	5,41	6,21	11,85	14,04	28,94	17,06	10,95	45,94	59,98	189
Oesophagus	0,00	0,00	0,00	0,00	0,00	6,54	0,00	5,26	6,52	0,00	6,21	5,93	0,00	0,00	8,53	0,00	22,97	29,99	513
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,93	14,04	5,79	25,59	0,00	0,00	0,00	390
Ovary	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,26	13,04	10,81	6,21	5,93	14,04	5,79	8,53	0,00	0,00	0,00	288
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,52	0,00	6,21	17,78	7,02	23,15	0,00	0,00	22,97	0,00	330
Primary site unknown	0,00	0,00	0,00	0,00	0,00	6,54	7,14	0,00	13,04	10,81	6,21	5,93	49,16	23,15	76,76	65,70	114,85	0,00	101
SCC of skin	0,00	0,00	0,00	0,00	0,00	6,54	0,00	0,00	19,56	10,81	31,07	29,63	63,20	40,52	144,99	87,60	206,73	479,81	58
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	11,85	0,00	0,00	0,00	0,00	0,00	0,00	1688
Skin other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,26	0,00	0,00	0,00	5,93	7,02	0,00	8,53	0,00	22,97	0,00	748
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,02	5,79	0,00	0,00	0,00	0,00	1562
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,26	6,52	5,41	0,00	5,93	14,04	5,79	0,00	0,00	22,97	0,00	466
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,41	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3697
Uterus	0,00	0,00	0,00	0,00	0,00	6,54	0,00	0,00	0,00	0,00	18,64	5,93	28,09	0,00	0,00	0,00	0,00	29,99	338
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,79	0,00	0,00	22,97	0,00	3455
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,41	0,00	0,00	0,00	5,79	0,00	10,95	45,94	0,00	1786

ALL MALES																			
Site	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**	**LR74**
All sites	4,20	3,21	4,39	6,97	7,46	13,85	35,09	48,36	80,14	155,78	237,58	388,64	562,97	712,61	894,30	958,93	1145,55	617,16	7
All sites but C44	4,20	2,41	4,39	6,10	7,46	13,25	32,28	41,92	65,42	127,19	196,53	327,05	452,66	590,20	742,56	643,11	756,29	352,66	8
Anus	0,00	0,00	0,00	0,00	0,00	0,00	1,40	0,64	4,09	0,00	3,73	4,40	1,90	0,00	0,00	5,74	0,00	0,00	1238
BCC	0,00	0,00	0,00	0,00	0,00	0,60	2,81	6,45	13,90	27,61	41,05	60,13	106,51	122,41	145,28	304,33	367,02	249,80	38
Bladder	0,70	0,00	0,00	0,00	0,00	0,00	0,00	2,58	1,64	2,96	1,24	11,73	19,02	13,12	19,37	28,71	44,49	0,00	277
Bone	0,00	0,00	0,00	0,00	0,00	0,00	1,40	0,00	0,82	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9010
Brain, CNS	0,00	0,00	0,88	0,87	0,00	0,00	0,00	1,93	3,27	0,99	4,98	4,40	0,00	8,74	0,00	5,74	11,12	0,00	768
Breast	0,00	0,00	0,00	0,00	0,00	0,00	2,11	0,64	0,00	1,97	1,24	2,93	11,41	8,74	0,00	5,74	11,12	0,00	689
Burkitt lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,99	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20203
Colorectal	0,70	0,00	0,00	0,87	0,00	3,01	7,72	2,58	9,81	11,83	19,90	22,00	24,73	52,46	64,57	40,19	55,61	29,39	91
Connective tissue	0,00	1,60	0,88	0,00	0,00	0,00	2,81	0,00	1,64	1,97	1,24	4,40	1,90	0,00	0,00	0,00	0,00	0,00	1217
Endocrine	0,00	0,00	0,00	0,00	0,68	0,00	0,00	0,00	0,00	0,00	2,49	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6310
Eye	1,40	0,00	0,00	0,00	0,00	0,60	1,40	1,29	0,00	5,92	1,24	2,93	1,90	0,00	3,23	0,00	0,00	0,00	1005
Gum	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,80	0,00	0,00	0,00	0,00	14,69	5264
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,23	5,74	11,12	14,69	6192
Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,60	0,70	1,29	0,82	1,97	2,49	4,40	0,00	2,19	0,00	0,00	0,00	0,00	1384
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,99	0,00	4,40	0,00	4,37	0,00	0,00	0,00	0,00	2050
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	1,81	2,81	5,80	4,09	4,93	4,98	1,47	3,80	4,37	6,46	0,00	0,00	0,00	494
Kidney	0,00	0,00	0,88	0,00	0,00	0,00	0,00	0,00	0,82	1,97	2,49	2,93	3,80	2,19	3,23	5,74	0,00	0,00	1093
Larynx	0,00	0,00	0,00	0,87	0,00	0,00	0,00	0,00	0,82	1,97	8,71	2,93	17,12	15,30	6,46	0,00	0,00	0,00	370
Leukaemia	0,00	0,80	0,00	0,00	2,71	0,60	0,00	0,00	0,00	1,97	1,24	0,00	1,90	6,56	6,46	11,48	0,00	14,69	900
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,47	0,00	0,00	0,00	0,00	0,00	0,00	13606
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,70	0,64	0,00	4,93	3,73	4,40	3,80	6,56	6,46	5,74	0,00	0,00	641
Lung	0,00	0,00	0,00	0,00	0,00	0,60	0,70	1,29	2,45	6,90	6,22	13,20	36,14	19,67	41,97	40,19	33,37	14,69	155
Melanoma	0,00	0,00	0,00	0,87	0,00	0,60	0,70	0,64	1,64	0,99	7,46	11,73	3,80	24,05	22,60	17,23	33,37	0,00	267

Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,14	0,00	0,00	0,00	1240
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,00	0,99	3,73	13,20	7,61	8,74	3,23	0,00	11,12	0,00	525
Myeloma	0,70	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,64	3,94	1,24	14,67	3,80	6,56	6,46	0,00	11,12	0,00	513
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,90	6,22	8,80	5,71	8,74	19,37	0,00	0,00	0,00	359
Non Hodgkin lymphoma	0,00	0,00	0,00	0,87	0,68	0,60	2,81	3,87	10,63	5,92	17,41	8,80	11,41	13,12	16,14	11,48	11,12	0,00	217
Oesophagus	0,00	0,00	0,00	0,00	2,03	1,20	0,70	0,64	1,64	4,93	9,95	16,13	9,51	26,23	32,29	11,48	11,12	14,69	191
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	1,40	0,64	0,00	1,97	3,73	1,47	7,61	4,37	9,69	5,74	0,00	0,00	648
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,82	3,94	2,49	7,33	11,41	2,19	12,91	0,00	11,12	0,00	480
Penis	0,70	0,00	0,00	0,00	0,68	0,00	0,00	1,93	0,00	5,92	0,00	7,33	3,80	0,00	0,00	5,74	0,00	0,00	983
Primary site unknown	0,00	0,00	1,75	1,74	0,00	0,60	0,70	2,58	6,54	10,85	12,44	19,07	28,53	34,97	29,06	11,48	22,24	0,00	135
Prostate	0,00	0,00	0,00	0,00	0,00	1,20	2,11	0,00	3,27	14,79	42,29	99,73	180,68	255,75	293,79	281,36	244,68	191,02	23
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,70	0,64	4,09	2,96	14,93	11,73	24,73	50,28	100,08	103,36	211,32	58,78	96
Salivary gland	0,00	0,80	0,00	0,87	0,00	0,00	0,00	0,00	0,82	0,00	0,00	1,47	1,90	0,00	6,46	11,48	11,12	14,69	1624
Skin other	0,00	0,00	0,00	0,00	0,68	0,00	0,00	0,64	0,82	0,99	0,00	2,93	0,00	6,56	0,00	5,74	22,24	0,00	1585
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,99	0,00	0,00	1,90	0,00	0,00	0,00	11,12	0,00	6921
Stomach	0,00	0,00	0,00	0,00	0,00	0,60	1,40	6,45	0,82	3,94	2,49	2,93	9,51	4,37	19,37	34,45	0,00	0,00	386
Testis	0,00	0,00	0,00	0,00	0,00	1,20	0,00	3,22	1,64	3,94	0,00	1,47	3,80	0,00	0,00	0,00	0,00	0,00	1310
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,82	0,00	1,24	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9709
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,64	0,82	1,97	4,98	11,73	9,51	0,00	0,00	0,00	0,00	0,00	675

ASIAN MALES																			
Site	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**	**LR74**
All sites	0,00	0,00	0,00	0,00	44,74	35,83	26,66	44,28	0,00	75,81	110,51	67,15	617,08	247,93	597,35	987,72	0,00	1425,27	11
All sites but C44	0,00	0,00	0,00	0,00	44,74	35,83	26,66	22,14	0,00	75,81	110,51	67,15	617,08	247,93	597,35	658,48	0,00	1425,27	11
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,14	0,00	0,00	0,00	0,00	0,00	0,00	0,00	329,24	0,00	0,00	904
Colorectal	0,00	0,00	0,00	0,00	0,00	35,83	26,66	0,00	0,00	0,00	0,00	0,00	88,15	123,97	0,00	0,00	0,00	0,00	73
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	37,91	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	528
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	37,91	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	528
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	88,15	0,00	199,12	0,00	0,00	0,00	70
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	67,15	0,00	0,00	0,00	0,00	0,00	0,00	298
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	55,25	0,00	176,31	0,00	0,00	0,00	0,00	0,00	87
Oesophagus	0,00	0,00	0,00	0,00	44,74	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	448
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	88,15	0,00	0,00	0,00	0,00	0,00	227
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	88,15	123,97	398,23	658,48	0,00	1425,27	33
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	55,25	0,00	0,00	0,00	0,00	0,00	0,00	0,00	362
Testis	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,14	0,00	0,00	0,00	0,00	88,15	0,00	0,00	0,00	0,00	0,00	182

BLACK MALES																			
Site	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**	**LR74**
All sites but C44	2,38	2,68	4,13	3,18	5,25	8,12	27,22	34,06	47,71	102,78	143,70	303,12	368,67	500,44	631,76	576,17	425,21	340,76	10
Anus	0,00	0,00	0,00	0,00	0,00	0,00	1,47	0,67	4,04	0,00	4,35	6,19	2,97	0,00	0,00	16,95	0,00	0,00	1016
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,06	5,95	7,25	0,00	0,00	0,00	0,00	1311
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,67	1,62	1,07	1,45	10,31	5,95	0,00	19,14	16,95	35,43	0,00	474
Bone	0,00	0,00	0,00	0,00	0,00	0,00	1,47	0,00	0,81	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8772
Brain, CNS	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	2,43	0,00	1,45	2,06	0,00	3,63	0,00	0,00	35,43	0,00	1954
Breast	0,00	0,00	0,00	0,00	0,00	0,00	2,21	0,67	0,00	1,07	0,00	2,06	8,92	3,63	0,00	0,00	0,00	0,00	1078
Burkitt lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,07	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18692
Colorectal	0,00	0,00	0,00	0,00	0,00	2,50	6,62	0,67	6,47	11,78	10,16	16,50	14,87	25,38	51,05	16,95	0,00	0,00	137
Connective tissue	0,00	1,79	1,03	0,00	0,00	0,00	2,94	0,00	0,81	0,00	1,45	4,12	0,00	0,00	0,00	0,00	0,00	0,00	1648
Endocrine	0,00	0,00	0,00	0,00	0,75	0,00	0,00	0,00	0,00	0,00	2,90	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5480
Eye	0,79	0,00	0,00	0,00	0,00	0,62	1,47	1,34	0,00	6,42	1,45	4,12	2,97	0,00	0,00	0,00	0,00	0,00	1043
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	35,43	0,00	
Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,62	0,74	1,34	0,81	2,14	1,45	6,19	0,00	3,63	0,00	0,00	0,00	0,00	1183
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,07	0,00	4,12	0,00	3,63	0,00	0,00	0,00	0,00	2268
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	1,25	1,47	6,01	4,04	5,35	5,81	2,06	2,97	7,25	12,76	0,00	0,00	0,00	409
Kidney	0,00	0,00	1,03	0,00	0,00	0,00	0,00	0,00	0,81	0,00	2,90	2,06	0,00	0,00	0,00	0,00	0,00	0,00	2942
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,81	2,14	8,71	4,12	26,76	14,51	12,76	0,00	0,00	0,00	287
Leukaemia	0,00	0,89	0,00	0,00	2,25	0,62	0,00	0,00	0,00	1,07	1,45	0,00	2,97	0,00	0,00	0,00	0,00	48,68	2163
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,06	0,00	0,00	0,00	0,00	0,00	0,00	9709
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,67	0,00	4,28	4,35	4,12	0,00	7,25	6,38	0,00	0,00	0,00	720
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,34	2,43	7,49	7,26	16,50	20,81	18,13	44,67	67,79	0,00	0,00	169
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,00	0,00	0,00	0,00	0,00	0,00	3,63	0,00	0,00	0,00	0,00	4577
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,38	0,00	0,00	0,00	3135
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,00	1,07	2,90	10,31	5,95	14,51	0,00	0,00	0,00	0,00	565

Myeloma	0,79	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,81	2,14	0,00	16,50	2,97	3,63	6,38	0,00	0,00	0,00	603
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,35	2,90	6,19	5,95	10,88	6,38	0,00	0,00	0,00	532
Non Hodgkin lymphoma	0,00	0,00	0,00	1,06	0,75	0,00	2,21	3,34	9,70	4,28	14,51	8,25	8,92	0,00	12,76	0,00	0,00	0,00	305
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,67	1,62	4,28	11,61	20,62	2,97	36,26	38,29	0,00	0,00	0,00	171
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,67	0,00	1,07	4,35	0,00	11,89	3,63	12,76	16,95	0,00	0,00	570
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,81	3,21	2,90	6,19	8,92	0,00	6,38	0,00	0,00	0,00	688
Penis	0,79	0,00	0,00	0,00	0,75	0,00	0,00	2,00	0,00	6,42	0,00	10,31	5,95	0,00	0,00	16,95	0,00	0,00	763
Primary site unknown	0,00	0,00	2,07	2,12	0,00	0,00	0,74	2,00	4,85	8,57	11,61	18,56	26,76	29,01	25,53	0,00	35,43	0,00	152
Prostate	0,00	0,00	0,00	0,00	0,00	1,25	1,47	0,00	1,62	10,71	29,03	92,79	175,42	293,74	370,12	389,76	283,47	292,08	21
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,67	2,43	0,00	4,35	2,06	2,97	7,25	0,00	0,00	0,00	0,00	978
Salivary gland	0,00	0,89	0,00	1,06	0,00	0,00	0,00	0,00	0,81	0,00	0,00	2,06	0,00	0,00	0,00	0,00	0,00	0,00	4150
Skin other	0,00	0,00	0,00	0,00	0,75	0,00	0,00	0,00	0,00	1,07	0,00	4,12	0,00	3,63	0,00	16,95	0,00	0,00	2090
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,97	0,00	0,00	0,00	0,00	0,00	6735
Stomach	0,00	0,00	0,00	0,00	0,00	0,62	0,74	6,68	0,81	4,28	1,45	2,06	11,89	7,25	0,00	16,95	0,00	0,00	559
Testis	0,00	0,00	0,00	0,00	0,00	0,62	0,00	0,00	0,00	4,28	0,00	2,06	0,00	0,00	0,00	0,00	0,00	0,00	2874
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,67	0,00	1,07	2,90	16,50	8,92	0,00	0,00	0,00	0,00	0,00	666

COLOURED MALES																			
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74
All sites	0,00	0,00	31,28	0,00	0,00	28,62	61,21	20,36	0,00	30,66	93,35	47,99	117,68	0,00	390,31	0,00	0,00	0,00	25
All sites but C44	0,00	0,00	31,28	0,00	0,00	28,62	61,21	20,36	0,00	30,66	93,35	47,99	117,68	0,00	390,31	0,00	0,00	0,00	25
Brain, CNS	0,00	0,00	31,28	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	640
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,36	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	983
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,00	61,21	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	327
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	117,68	0,00	195,15	0,00	0,00	0,00	64
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	47,99	0,00	0,00	0,00	0,00	0,00	0,00	417
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	28,62	0,00	0,00	0,00	0,00	46,67	0,00	0,00	0,00	0,00	0,00	0,00	0,00	266
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	30,66	46,67	0,00	0,00	0,00	195,15	0,00	0,00	0,00	74

WHITE MALES																			
Site	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**	**LR74**
All sites	17,68	0,00	0,00	29,03	14,27	58,92	62,49	115,12	196,11	294,98	530,53	691,70	1173,32	1066,73	1535,34	1869,89	3839,93	2275,74	4
All sites but C44	17,68	0,00	0,00	29,03	14,27	51,55	34,72	65,78	103,50	147,49	331,58	444,66	774,69	754,37	1118,22	1087,15	2389,29	1103,39	6
BCC	0,00	0,00	0,00	0,00	0,00	7,36	27,77	49,34	92,61	142,41	198,95	247,04	391,11	312,36	399,36	753,75	1365,31	1103,39	11
Bladder	8,84	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,17	0,00	18,53	52,65	35,36	26,62	57,98	128,00	0,00	132
Brain, CNS	0,00	0,00	0,00	7,26	0,00	0,00	0,00	10,96	5,45	5,09	18,09	12,35	0,00	17,68	0,00	14,50	0,00	0,00	261
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,09	6,03	6,18	22,56	17,68	0,00	14,50	42,67	0,00	348
Colorectal	8,84	0,00	0,00	7,26	0,00	0,00	0,00	10,96	16,34	5,09	54,26	43,23	52,65	94,30	106,50	86,97	213,33	137,92	51
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,45	10,17	0,00	6,18	7,52	0,00	0,00	0,00	0,00	0,00	683
Eye	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,87	0,00	0,00	0,00	2255
Gum	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	15,04	0,00	0,00	0,00	0,00	68,96	1330
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,87	14,50	0,00	68,96	2255
Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,03	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3317
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,18	0,00	5,89	0,00	0,00	0,00	0,00	1658
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	7,36	0,00	0,00	0,00	0,00	0,00	0,00	7,52	0,00	0,00	0,00	0,00	0,00	1345
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,09	0,00	6,18	15,04	5,89	8,87	14,50	0,00	0,00	487
Larynx	0,00	0,00	0,00	7,26	0,00	0,00	0,00	0,00	0,00	0,00	6,03	0,00	0,00	17,68	0,00	0,00	0,00	0,00	646
Leukaemia	0,00	0,00	0,00	0,00	7,14	0,00	0,00	0,00	0,00	5,09	0,00	0,00	0,00	17,68	17,75	28,99	0,00	0,00	420
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,18	15,04	5,89	8,87	14,50	0,00	0,00	556
Lung	0,00	0,00	0,00	0,00	0,00	7,36	6,94	0,00	0,00	0,00	0,00	6,18	75,21	23,57	35,50	43,49	128,00	68,96	130
Melanoma	0,00	0,00	0,00	7,26	0,00	7,36	0,00	5,48	10,89	5,09	36,17	49,41	15,04	53,04	62,12	43,49	128,00	0,00	80
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	35,50	0,00	0,00	0,00	564
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6,03	18,53	15,04	0,00	8,87	0,00	42,67	0,00	413
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,45	10,17	6,03	6,18	7,52	11,79	8,87	0,00	42,67	0,00	358
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,17	18,09	12,35	7,52	5,89	44,37	0,00	0,00	0,00	204
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	6,94	5,48	5,45	5,09	12,06	12,35	7,52	35,36	26,62	14,50	42,67	0,00	172

Oesophagus	0,00	0,00	0,00	0,00	7,14	14,73	0,00	0,00	0,00	5,09	0,00	0,00	30,09	11,79	35,50	28,99	42,67	68,96	192
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	6,94	0,00	0,00	5,09	0,00	6,18	0,00	5,89	8,87	0,00	0,00	0,00	607
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,09	0,00	12,35	22,56	5,89	26,62	0,00	42,67	0,00	276
Primary site unknown	0,00	0,00	0,00	0,00	0,00	7,36	0,00	5,48	10,89	15,26	12,06	24,70	37,61	47,15	44,37	28,99	42,67	0,00	98
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	6,94	0,00	5,45	20,34	78,37	142,05	248,20	206,27	266,24	347,89	597,32	413,77	21
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,89	15,26	54,26	43,23	90,26	117,87	275,12	260,92	810,65	275,85	33
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,52	0,00	17,75	28,99	42,67	68,96	792
Skin other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,48	5,45	0,00	0,00	0,00	0,00	11,79	0,00	0,00	85,33	0,00	881
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,09	0,00	0,00	0,00	0,00	0,00	0,00	42,67	0,00	3930
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	6,94	0,00	0,00	0,00	0,00	6,18	7,52	0,00	53,25	72,48	0,00	0,00	271
Testis	0,00	0,00	0,00	0,00	0,00	7,36	0,00	21,93	10,89	0,00	0,00	0,00	7,52	0,00	0,00	0,00	0,00	0,00	420
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,45	0,00	6,03	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1743
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5,45	5,09	12,06	0,00	15,04	0,00	0,00	0,00	0,00	0,00	532

Frequency of Cancer by Age Group

ALL FEMALES																				
Site	**All Ages**	**Unknown Ages**	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**
All sites	2526	0	5	7	7	10	13	57	130	248	236	296	215	244	314	246	224	119	95	60
All sites but C44	2278	0	5	7	7	6	12	54	122	242	220	278	206	217	279	210	202	91	75	45
Anus	23	0	0	0	0	0	0	0	1	5	0	6	1	2	2	4	0	0	1	1
BCC	235	0	0	0	0	1	0	3	6	6	15	18	9	25	34	35	20	28	20	15
Bladder	17	0	0	0	0	0	0	0	0	2	2	0	1	1	3	4	2	1	1	0
Bone	5	0	0	2	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0
Brain, CNS	21	0	1	1	2	0	0	2	2	1	0	0	3	3	1	0	2	0	2	1
Breast	636	0	0	0	0	0	2	18	28	68	72	96	62	54	78	52	55	29	14	8
Cervix	553	0	2	0	0	0	0	11	41	81	79	87	59	72	59	26	20	9	6	1
Colorectal	115	0	0	0	0	0	0	0	6	3	1	7	17	10	22	15	14	9	8	3
Connective tissue	10	0	0	0	1	0	1	3	0	1	2	1	0	0	1	0	0	0	0	0
Endocrine	6	0	1	0	2	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0
Eye	10	0	0	1	0	0	0	0	1	2	5	0	0	0	1	0	0	0	0	0
Haematology other	6	0	0	0	0	0	0	0	1	1	0	0	0	3	0	0	0	0	1	0
Hodgkin lymphoma	19	0	0	0	0	2	2	0	1	6	2	2	1	0	0	1	1	0	1	0
Ill defined	6	0	0	0	0	0	1	0	0	0	2	0	0	1	1	1	0	0	0	0
Kaposi Sarcoma	17	0	0	0	0	0	0	2	2	5	2	2	1	1	1	1	0	0	0	0
Kidney	7	0	1	1	0	0	0	0	0	0	0	0	1	0	0	2	2	0	0	0
Larynx	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1
Leukaemia	13	0	0	1	0	0	0	1	1	1	0	1	0	1	2	1	2	1	1	0

Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
Liver & Bile duct	27	0	0	0	0	0	0	0	0	2	2	6	5	0	3	3	5	0	1	0
Lung	38	0	0	0	0	0	0	1	1	0	0	1	0	3	6	10	11	3	2	0
Melanoma	41	0	0	0	0	0	0	0	1	2	0	1	3	1	9	5	12	6	0	1
Mesothelioma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	6	0	0
Mouth	7	0	0	0	0	0	0	0	1	0	0	0	1	0	2	2	0	0	1	0
Myeloma	14	0	0	0	0	0	0	0	0	0	1	0	0	4	0	3	2	1	3	0
Naso-Oropharynx	11	0	0	0	0	1	0	0	0	2	1	0	0	2	2	0	3	0	0	0
Non Hodgkin lymphoma	58	0	0	1	1	1	4	2	7	8	4	5	3	3	4	6	3	1	2	3
Oesophagus	42	0	0	0	0	0	0	1	1	1	2	2	9	3	1	11	7	1	1	2
Other specified	36	0	0	0	0	0	1	3	4	3	1	2	5	3	4	4	4	1	1	0
Ovary	40	0	0	0	1	1	0	2	3	6	4	5	4	2	3	7	2	0	0	0
Pancreas	26	0	0	0	0	0	0	0	0	0	1	2	2	7	4	7	1	0	1	1
Primary site unknown	119	0	0	0	0	1	1	5	3	7	5	15	8	12	17	13	14	10	7	1
SCC of skin	111	0	0	0	0	0	0	1	4	4	9	8	5	7	12	8	18	9	9	17
Salivary gland	12	0	0	0	0	3	1	0	2	0	1	0	0	2	1	1	1	0	0	0
Skin other	11	0	0	0	0	0	0	0	0	2	0	0	1	3	1	0	2	0	1	1
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Stomach	16	0	0	0	0	0	0	0	2	1	1	3	1	1	2	5	0	0	0	0
Thyroid	18	0	0	0	0	0	0	0	2	3	1	3	0	3	3	2	0	0	1	0
Tongue	6	0	0	0	0	0	0	0	0	0	0	2	1	1	0	0	1	0	0	1
Uterus	90	0	0	0	0	0	0	1	0	3	2	3	5	8	30	13	13	3	6	3
Vagina	16	0	0	0	0	0	0	0	3	1	0	5	1	1	1	1	2	0	1	0
Vulva	75	0	0	0	0	0	0	1	6	20	17	12	6	3	2	1	4	1	2	0

ASIAN FEMALES																				
Site	**All Ages**	**Unknown Ages**	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**
All sites	22	0	0	0	0	0	0	0	1	2	2	4	3	1	5	4	0	0	0	0
All sites but C44	21	0	0	0	0	0	0	0	1	2	2	4	3	1	4	4	0	0	0	0
BCC	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Breast	8	0	0	0	0	0	0	0	0	1	2	2	0	0	2	1	0	0	0	0
Colorectal	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0
Liver & Bile duct	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Non Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Other specified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Ovary	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Pancreas	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Primary site unknown	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Thyroid	2	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0
Tongue	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Uterus	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0

BLACK FEMALES																				
Site	**All Ages**	**Unknown Ages**	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**
All sites	1600	0	4	5	4	8	11	46	109	212	192	232	147	157	181	126	93	31	27	15
All sites but C44	1573	0	4	5	4	5	10	45	106	212	190	226	147	153	179	125	90	30	27	15
Anus	14	0	0	0	0	0	0	0	1	5	0	3	0	2	2	1	0	0	0	0
BCC	16	0	0	0	0	0	0	1	1	0	1	6	0	4	1	0	1	1	0	0
Bladder	5	0	0	0	0	0	0	0	0	1	2	0	0	0	1	1	0	0	0	0
Bone	4	0	0	2	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0
Brain, CNS	7	0	1	1	0	0	0	0	2	0	0	0	1	1	0	0	0	0	1	0
Breast	429	0	0	0	0	0	2	18	25	56	60	75	44	29	47	32	24	9	5	3
Cervix	506	0	1	0	0	0	0	10	38	77	74	77	53	68	53	21	19	8	6	1
Colorectal	54	0	0	0	0	0	0	0	3	2	1	5	9	4	16	5	3	2	3	1
Connective tissue	8	0	0	0	1	0	1	3	0	0	2	1	0	0	0	0	0	0	0	0
Endocrine	4	0	1	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
Eye	10	0	0	1	0	0	0	0	1	2	5	0	0	0	1	0	0	0	0	0
Haematology other	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Hodgkin lymphoma	12	0	0	0	0	1	0	0	1	5	2	2	0	0	0	0	1	0	0	0
Ill defined	6	0	0	0	0	0	1	0	0	0	2	0	0	1	1	1	0	0	0	0
Kaposi Sarcoma	15	0	0	0	0	0	0	2	1	5	2	2	1	1	0	1	0	0	0	0
Kidney	4	0	1	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0	0
Larynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Leukaemia	7	0	0	1	0	0	0	0	1	0	0	1	0	1	0	1	0	1	1	0
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0

Liver & Bile duct	18	0	0	0	0	0	0	0	0	2	1	6	4	0	2	2	1	0	0	0
Lung	11	0	0	0	0	0	0	0	0	0	0	0	0	3	1	4	3	0	0	0
Melanoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	1	0	0
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Mouth	4	0	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0	0	1	0
Myeloma	3	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0
Naso-Oropharynx	9	0	0	0	0	1	0	0	0	2	1	0	0	2	2	0	1	0	0	0
Non Hodgkin lymphoma	35	0	0	0	1	1	4	2	6	8	3	3	1	1	2	1	1	0	0	1
Oesophagus	33	0	0	0	0	0	0	0	1	0	1	2	7	2	1	11	6	1	0	1
Other specified	27	0	0	0	0	0	1	3	4	3	1	2	5	2	1	2	1	1	1	0
Ovary	27	0	0	0	1	1	0	2	3	5	2	3	2	1	1	5	1	0	0	0
Pancreas	14	0	0	0	0	0	0	0	0	0	0	2	0	4	3	3	1	0	0	1
Primary site unknown	78	0	0	0	0	1	1	4	2	7	3	12	7	11	10	8	5	4	2	1
SCC of skin	26	0	0	0	0	0	0	0	4	4	6	6	0	1	2	1	1	0	0	1
Salivary gland	10	0	0	0	0	3	1	0	2	0	1	0	0	0	1	1	1	0	0	0
Skin other	6	0	0	0	0	0	0	0	0	1	0	0	1	2	0	0	1	0	0	1
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Stomach	14	0	0	0	0	0	0	0	2	1	1	3	1	1	1	4	0	0	0	0
Thyroid	8	0	0	0	0	0	0	0	1	1	0	2	0	2	1	1	0	0	0	0
Tongue	4	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	1
Uterus	78	0	0	0	0	0	0	0	0	3	2	2	2	6	26	13	13	3	6	2
Vagina	13	0	0	0	0	0	0	0	3	1	0	5	0	1	1	0	2	0	0	0
Vulva	70	0	0	0	0	0	0	1	6	20	17	11	6	3	2	0	4	0	0	0

COLOURED FEMALES																				
Site	**All Ages**	**Unknown Ages**	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**
All sites	37	0	1	0	0	1	0	0	2	2	1	6	7	4	1	8	4	0	0	0
All sites but C44	36	0	1	0	0	1	0	0	2	2	1	6	6	4	1	8	4	0	0	0
BCC	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Bladder	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Breast	13	0	0	0	0	0	0	0	0	0	0	2	2	2	1	5	1	0	0	0
Cervix	9	0	1	0	0	0	0	0	2	1	1	2	1	1	0	0	0	0	0	0
Colorectal	4	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	1	0	0	0
Hodgkin lymphoma	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukaemia	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Liver & Bile duct	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Lung	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Non Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Oesophagus	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Primary site unknown	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Uterus	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Vagina	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0

WHITE FEMALES																				
Site	**All Ages**	**Unknown Ages**	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**
All sites	843	0	0	2	2	1	2	11	17	31	39	53	56	81	121	107	124	86	66	44
All sites but C44	632	0	0	2	2	0	2	9	13	25	26	42	48	58	90	73	106	59	47	30
Anus	9	0	0	0	0	0	0	0	0	0	0	3	1	0	0	3	0	0	1	1
BCC	209	0	0	0	0	1	0	2	4	6	13	11	8	21	31	34	18	27	19	14
Bladder	11	0	0	0	0	0	0	0	0	1	0	0	1	0	2	3	2	1	1	0
Bone	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Brain, CNS	14	0	0	0	2	0	0	2	0	1	0	0	2	2	1	0	2	0	1	1
Breast	185	0	0	0	0	0	0	0	3	11	10	17	16	23	28	14	29	20	9	5
Cervix	33	0	0	0	0	0	0	1	1	3	3	8	4	3	4	5	1	0	0	0
Colorectal	53	0	0	0	0	0	0	0	3	0	0	2	6	6	5	8	10	7	4	2
Connective tissue	2	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0
Endocrine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Haematology other	4	0	0	0	0	0	0	0	1	0	0	0	0	2	0	0	0	0	1	0
Hodgkin lymphoma	6	0	0	0	0	0	2	0	0	1	0	0	1	0	0	1	0	0	1	0
Kaposi Sarcoma	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Kidney	3	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Leukaemia	5	0	0	0	0	0	0	1	0	1	0	0	0	0	2	0	1	0	0	0
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Liver & Bile duct	7	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	3	0	1	0
Lung	25	0	0	0	0	0	0	1	1	0	0	1	0	0	5	5	7	3	2	0

Melanoma	36	0	0	0	0	0	0	0	1	2	0	1	3	1	9	1	12	5	0	1
Mesothelioma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0
Mouth	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0
Myeloma	11	0	0	0	0	0	0	0	0	0	0	0	0	3	0	3	1	1	3	0
Naso-Oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
Non Hodgkin lymphoma	21	0	0	1	0	0	0	0	1	0	1	1	1	2	2	5	2	1	2	2
Oesophagus	8	0	0	0	0	0	0	1	0	1	1	0	1	1	0	0	1	0	1	1
Other specified	7	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	3	0	0	0
Ovary	11	0	0	0	0	0	0	0	0	1	2	2	1	1	2	1	1	0	0	0
Pancreas	11	0	0	0	0	0	0	0	0	0	1	0	1	3	1	4	0	0	1	0
Primary site unknown	39	0	0	0	0	0	0	1	1	0	2	2	1	1	7	4	9	6	5	0
SCC of skin	82	0	0	0	0	0	0	1	0	0	3	2	5	5	9	7	17	8	9	16
Salivary gland	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0
Skin other	5	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	1	0	1	0
Stomach	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0
Thyroid	8	0	0	0	0	0	0	0	0	1	1	1	0	1	2	1	0	0	1	0
Tongue	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Uterus	10	0	0	0	0	0	0	1	0	0	0	0	3	1	4	0	0	0	0	1
Vagina	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0
Vulva	5	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	2	0

ALL MALES																				
Site	**All Ages**	**Unknown Ages**	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**
All sites	2105	0	6	4	5	8	11	23	50	75	98	158	191	265	296	326	277	167	103	42
All sites but C44	1697	0	6	3	5	7	11	22	46	65	80	129	158	223	238	270	230	112	68	24
Anus	16	0	0	0	0	0	0	0	2	1	5	0	3	3	1	0	0	1	0	0
BCC	394	0	0	0	0	0	0	1	4	10	17	28	33	41	56	56	45	53	33	17
Bladder	50	0	1	0	0	0	0	0	0	4	2	3	1	8	10	6	6	5	4	0
Bone	3	0	0	0	0	0	0	0	2	0	1	0	0	0	0	0	0	0	0	0
Brain, CNS	23	0	0	0	1	1	0	0	0	3	4	1	4	3	0	4	0	1	1	0
Breast	21	0	0	0	0	0	0	0	3	1	0	2	1	2	6	4	0	1	1	0
Burkitt lymphoma	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Colorectal	148	0	1	0	0	1	0	5	11	4	12	12	16	15	13	24	20	7	5	2
Connective tissue	16	0	0	2	1	0	0	0	4	0	2	2	1	3	1	0	0	0	0	0
Endocrine	3	0	0	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	0
Eye	18	0	2	0	0	0	0	1	2	2	0	6	1	2	1	0	1	0	0	0
Gum	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1
Haematology other	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1
Hodgkin lymphoma	13	0	0	0	0	0	0	1	1	2	1	2	2	3	0	1	0	0	0	0
Ill defined	6	0	0	0	0	0	0	0	0	0	0	1	0	3	0	2	0	0	0	0
Kaposi Sarcoma	37	0	0	0	0	0	0	3	4	9	5	5	4	1	2	2	2	0	0	0
Kidney	13	0	0	0	1	0	0	0	0	0	1	2	2	2	2	1	1	1	0	0
Larynx	31	0	0	0	0	1	0	0	0	0	1	2	7	2	9	7	2	0	0	0
Leukaemia	18	0	0	1	0	0	4	1	0	0	0	2	1	0	1	3	2	2	0	1

Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Liver & Bile duct	21	0	0	0	0	0	0	0	1	1	0	5	3	3	2	3	2	1	0	0
Lung	80	0	0	0	0	0	0	1	1	2	3	7	5	9	19	9	13	7	3	1
Melanoma	47	0	0	0	0	1	0	1	1	1	2	1	6	8	2	11	7	3	3	0
Mesothelioma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	0	0	0
Mouth	24	0	0	0	0	0	0	0	0	1	0	1	3	9	4	4	1	0	1	0
Myeloma	26	0	1	0	0	0	0	0	0	0	2	4	1	10	2	3	2	0	1	0
Naso-Oropharynx	31	0	0	0	0	0	0	0	0	0	0	7	5	6	3	4	6	0	0	0
Non Hodgkin lymphoma	72	0	0	0	0	1	1	1	4	6	13	6	14	6	6	6	5	2	1	0
Oesophagus	64	0	0	0	0	0	3	2	1	1	2	5	8	11	5	12	10	2	1	1
Other specified	19	0	0	0	0	0	0	0	2	1	0	2	3	1	4	2	3	1	0	0
Pancreas	25	0	0	0	0	0	0	0	0	1	1	4	2	5	6	1	4	0	1	0
Penis	19	0	1	0	0	0	1	0	0	3	0	6	0	5	2	0	0	1	0	0
Primary site unknown	96	0	0	0	2	2	0	1	1	4	8	11	10	13	15	16	9	2	2	0
Prostate	513	0	0	0	0	0	0	2	3	0	4	15	34	68	95	117	91	49	22	13
SCC of skin	138	0	0	0	0	0	0	0	1	1	5	3	12	8	13	23	31	18	19	4
Salivary gland	11	0	0	1	0	1	0	0	0	0	1	0	0	1	1	0	2	2	1	1
Skin other	12	0	0	0	0	0	1	0	0	1	1	1	0	2	0	3	0	1	2	0
Small intestine	3	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0
Stomach	41	0	0	0	0	0	0	1	2	10	1	4	2	2	5	2	6	6	0	0
Testis	16	0	0	0	0	0	0	2	0	5	2	4	0	1	2	0	0	0	0	0
Thyroid	2	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0
Tongue	21	0	0	0	0	0	0	0	0	1	1	2	4	8	5	0	0	0	0	0

ASIAN MALES																				
Site	**All Ages**	**Unknown Ages**	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**
All sites	26	0	0	0	0	0	1	1	1	2	0	2	2	1	7	2	3	3	0	1
All sites but C44	24	0	0	0	0	0	1	1	1	1	0	2	2	1	7	2	3	2	0	1
BCC	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0
Colorectal	4	0	0	0	0	0	0	1	1	0	0	0	0	0	1	1	0	0	0	0
Kidney	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Liver & Bile duct	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Lung	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
Mouth	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Non Hodgkin lymphoma	3	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0
Oesophagus	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Primary site unknown	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Prostate	7	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	2	0	1
Stomach	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Testis	2	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0

BLACK MALES																				
Site	**All Ages**	**Unknown Ages**	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**
All sites	946	0	3	4	4	4	7	13	37	51	60	96	99	149	127	140	99	34	12	7
All sites but C44	936	0	3	3	4	3	7	13	37	51	59	96	99	147	124	138	99	34	12	7
Anus	16	0	0	0	0	0	0	0	2	1	5	0	3	3	1	0	0	1	0	0
BCC	5	0	0	0	0	0	0	0	0	0	0	0	0	1	2	2	0	0	0	0
Bladder	20	0	0	0	0	0	0	0	0	4	2	1	1	5	2	0	3	1	1	0
Bone	3	0	0	0	0	0	0	0	2	0	1	0	0	0	0	0	0	0	0	0
Brain, CNS	8	0	0	0	0	0	0	0	0	1	3	0	1	1	0	1	0	0	1	0
Breast	10	0	0	0	0	0	0	0	3	1	0	1	0	1	3	1	0	0	0	0
Burkitt lymphoma	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Colorectal	69	0	0	0	0	0	0	4	9	1	8	11	7	8	5	7	8	1	0	0
Connective tissue	11	0	0	2	1	0	0	0	4	0	1	0	1	2	0	0	0	0	0	0
Endocrine	3	0	0	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	0
Eye	16	0	1	0	0	0	0	1	2	2	0	6	1	2	1	0	0	0	0	0
Haematology other	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Hodgkin lymphoma	12	0	0	0	0	0	0	1	1	2	1	2	1	3	0	1	0	0	0	0
Ill defined	4	0	0	0	0	0	0	0	0	0	0	1	0	2	0	1	0	0	0	0
Kaposi Sarcoma	33	0	0	0	0	0	0	2	2	9	5	5	4	1	1	2	2	0	0	0
Kidney	5	0	0	0	1	0	0	0	0	0	1	0	2	1	0	0	0	0	0	0
Larynx	26	0	0	0	0	0	0	0	0	0	1	2	6	2	9	4	2	0	0	0
Leukaemia	9	0	0	1	0	0	3	1	0	0	0	1	1	0	1	0	0	0	0	1
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0

Liver & Bile duct	14	0	0	0	0	0	0	0	1	1	0	4	3	2	0	2	1	0	0	0
Lung	48	0	0	0	0	0	0	0	0	2	3	7	5	8	7	5	7	4	0	0
Melanoma	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Mouth	15	0	0	0	0	0	0	0	0	1	0	1	2	5	2	4	0	0	0	0
Myeloma	15	0	1	0	0	0	0	0	0	0	1	2	0	8	1	1	1	0	0	0
Naso-Oropharynx	16	0	0	0	0	0	0	0	0	0	0	5	2	3	2	3	1	0	0	0
Non Hodgkin lymphoma	45	0	0	0	0	1	1	0	3	5	12	4	10	4	3	0	2	0	0	0
Oesophagus	43	0	0	0	0	0	0	0	1	1	2	4	8	10	1	10	6	0	0	0
Other specified	14	0	0	0	0	0	0	0	1	1	0	1	3	0	4	1	2	1	0	0
Pancreas	14	0	0	0	0	0	0	0	0	1	1	3	2	3	3	0	1	0	0	0
Penis	19	0	1	0	0	0	1	0	0	3	0	6	0	5	2	0	0	1	0	0
Primary site unknown	61	0	0	0	2	2	0	0	1	3	6	8	8	9	9	8	4	0	1	0
Prostate	316	0	0	0	0	0	0	2	2	0	2	10	20	45	59	81	58	23	8	6
SCC of skin	12	0	0	0	0	0	0	0	1	1	3	0	3	1	1	2	0	0	0	0
Salivary gland	4	0	0	1	0	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0
Skin other	6	0	0	0	0	0	1	0	0	0	0	1	0	2	0	1	0	1	0	0
Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Stomach	26	0	0	0	0	0	0	1	1	10	1	4	1	1	4	2	0	1	0	0
Testis	6	0	0	0	0	0	0	1	0	0	0	4	0	1	0	0	0	0	0	0
Tongue	15	0	0	0	0	0	0	0	0	1	0	1	2	8	3	0	0	0	0	0

COLOURED MALES																				
Site	**All Ages**	**Unknown Ages**	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**
All sites	12	0	0	0	1	0	0	1	2	1	0	1	2	1	1	0	2	0	0	0
All sites but C44	12	0	0	0	1	0	0	1	2	1	0	1	2	1	1	0	2	0	0	0
Brain, CNS	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Colorectal	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Kaposi Sarcoma	2	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0
Lung	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
Naso-Oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Non Hodgkin lymphoma	2	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0
Prostate	3	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0

WHITE MALES																				
Site	**All Ages**	**Unknown Ages**	**0-4**	**05-09**	**10-14**	**15-19**	**20-24**	**25-29**	**30-34**	**35-39**	**40-44**	**45-49**	**50-54**	**55-59**	**60-64**	**65-69**	**70-74**	**75-79**	**80-85**	**85+**
All sites	1102	0	2	0	0	4	2	8	9	21	36	58	88	112	156	181	173	129	90	33
All sites but C44	711	0	2	0	0	4	2	7	5	12	19	29	55	72	103	128	126	75	56	16
BCC	382	0	0	0	0	0	0	1	4	9	17	28	33	40	52	53	45	52	32	16
Bladder	29	0	1	0	0	0	0	0	0	0	0	2	0	3	7	6	3	4	3	0
Brain, CNS	14	0	0	0	0	1	0	0	0	2	1	1	3	2	0	3	0	1	0	0
Breast	11	0	0	0	0	0	0	0	0	0	0	1	1	1	3	3	0	1	1	0
Colorectal	72	0	1	0	0	1	0	0	0	2	3	1	9	7	7	16	12	6	5	2
Connective tissue	5	0	0	0	0	0	0	0	0	0	1	2	0	1	1	0	0	0	0	0
Eye	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Gum	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1
Haematology other	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1
Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Ill defined	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
Kaposi Sarcoma	2	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0
Kidney	7	0	0	0	0	0	0	0	0	0	0	1	0	1	2	1	1	1	0	0
Larynx	5	0	0	0	0	1	0	0	0	0	0	0	1	0	0	3	0	0	0	0
Leukaemia	9	0	0	0	0	0	1	0	0	0	0	1	0	0	0	3	2	2	0	0
Liver & Bile duct	6	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	1	1	0	0
Lung	28	0	0	0	0	0	0	1	1	0	0	0	0	1	10	4	4	3	3	1
Melanoma	44	0	0	0	0	1	0	1	0	1	2	1	6	8	2	9	7	3	3	0
Mesothelioma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	0	0

Mouth	8	0	0	0	0	0	0	0	0	0	0	0	1	3	2	0	1	0	1	0
Myeloma	10	0	0	0	0	0	0	0	0	0	1	2	1	1	1	2	1	0	1	0
Naso-Oropharynx	14	0	0	0	0	0	0	0	0	0	0	2	3	2	1	1	5	0	0	0
Non Hodgkin lymphoma	20	0	0	0	0	0	0	0	1	1	1	1	2	2	1	6	3	1	1	0
Oesophagus	18	0	0	0	0	0	1	2	0	0	0	1	0	0	4	2	4	2	1	1
Other specified	5	0	0	0	0	0	0	0	1	0	0	1	0	1	0	1	1	0	0	0
Pancreas	11	0	0	0	0	0	0	0	0	0	0	1	0	2	3	1	3	0	1	0
Primary site unknown	34	0	0	0	0	0	0	1	0	1	2	3	2	4	5	8	5	2	1	0
Prostate	184	0	0	0	0	0	0	0	1	0	1	4	13	23	33	35	30	24	14	6
SCC of skin	125	0	0	0	0	0	0	0	0	0	2	3	9	7	12	20	31	18	19	4
Salivary gland	7	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	2	1	1
Skin other	6	0	0	0	0	0	0	0	0	1	1	0	0	0	0	2	0	0	2	0
Small intestine	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0
Stomach	14	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	6	5	0	0
Testis	8	0	0	0	0	0	0	1	0	4	2	0	0	0	1	0	0	0	0	0
Thyroid	2	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0
Tongue	6	0	0	0	0	0	0	0	0	0	1	1	2	0	2	0	0	0	0	0